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Individuals treated for multidrug-resistant tuberculosis (MDR-TB) with 
aminoglycosides (AGs) in resource-limited settings often experience permanent hearing 
loss, but there is no practical, cost-effective means to identify those at higher risk. This 
dissertation aimed to estimate the risk of AG-induced hearing loss for MDR-TB-infected 
individuals in South Africa.  
Methods 
We nested this analysis within a cluster randomized trial of nurse-led case 
management in 10 South African TB hospitals. All participants ≥13 years old received 
kanamycin or amikacin. Hearing loss was defined as a poorer hearing threshold 
compared to baseline clinical and audiometric evaluation. We developed the prediction 
model using data from 265 patients at hearing frequencies from 250 to 8,000Hz and 
validated the model using data from 114 separate patients at both normal (250-8,000Hz) 
and ultrahigh frequencies (9,000-16,000Hz). We estimated standardized weekly AG 
exposure as: 
{prescribed daily AG dose (mg) x frequency of dosing per week} ÷ weight (kg) 
Cox proportional hazard and logistic regression were used for multivariable adjustment. 
Results 
Of 936 participants, 54% were male; mean age was 36 years; 75% were HIV 
coinfected at baseline. Comparing patients with high (≥75mg/kg/week) versus low 
(<75mg/kg/week) AG exposure, the adjusted hazard (aHR) of regimen cessation due to 
ototoxicity was 1.33 (p=0.006); aHR for audiometric hearing loss was 1.34 (p=.038). Pre-
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existing hearing loss (aHR=1.71, p<.001) and age (aHR=1.02, p=.031) were also 
associated with increased hazard of hearing loss. Predictors of ototoxicity in the final 
prediction model included: standardized weekly AG exposure, HIV status, CD4 count, 
age, serum albumin, BMI, and pre-existing hearing loss. This model demonstrated 
moderate discrimination (AUC=0.72) and good calibration (χ2[8]=6.10, p=.64) at normal 
frequencies and better discrimination (AUC=0.81) at ultrahigh frequencies that might 
represent early manifestations of AG ototoxicity. Discrimination for AG regimen 
cessation due to ototoxicity (among 671 patients without baseline audiometric data) was 
weaker (AUC=0.60). Using a cutoff of 85% predicted probability of hearing loss, the 
positive predictive value was 100% and the negative predictive value was 41%. 
Conclusions 
This model identifies patients at high risk for AG-induced hearing loss and may 
inform clinical guidelines regarding which patients to prioritize for injectable-free 
regimens. 
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CHAPTER 1: INTRODUCTION 
In many low- and middle-income countries, tuberculosis (TB) remains the leading 
cause of death. Drug-resistant tuberculosis (DR-TB) has the potential to increase the 
length and intensity of treatment, reduce patients’ quality of life, and increase the 
likelihood of mortality. DR-TB is known as multidrug-resistant (MDR-TB) TB and is 
resistant to both first-line anti-TB drugs (isoniazid and rifampicin)—and extensively 
drug-resistant (XDR-TB)—TB resistant to core second-line anti-TB drugs (i.e., 
fluoroquinolones and injectable agents).1 In particular, the World Health Organization 
(WHO) recommendations for rifampicin-resistant (RR-TB) or MDR-TB treatment 
currently include second-line anti-TB drugs and is divided into two phases: (1) the 
intensive phase is at least 4 months (up to 6 months) and includes an injectable agent 
either aminoglycoside (AG) (e.g., kanamycin or amikacin) or capreomycin along with 6-
7 oral drugs, (2) the continuation phase includes daily oral drugs for at least 5 months.1 
MDR-TB treatment regimens in South Africa have evolved based on WHO guidelines; 
however, newer short-course regimens requiring only 9 months of treatment, while 
traditional longer regimens for 18 to 20 months, are still used for some patients.2 During 
the first 4-6 months of the intensive phase, a large proportion of MDR-TB patients 
develop permanent hearing loss due to ototoxic effects from AG.3,4 AG ototoxicity may 
cause early AG regimen modification (i.e., reduced or discontinued), leading to failed or 
delayed TB culture conversion due to attenuated bactericidal efficacy of AG, particularly 
in resource-limited settings without a substitute for AG. AG-induced hearing loss 
typically presents with high-frequency hearing loss, which may be accompanied by 
tinnitus, prior to presentation of hearing loss in audible lower frequencies. It is often 
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under-detected if audiological evaluation is not available or inconsistently performed.5,6 
Myriad therapeutic efforts have been proposed to target various steps of the complex 
cascade of AG ototoxicity; however, clinical application is impractical in many resource-
limited settings. The exact mechanism of AG ototoxicity is unknown, but it has been 
hypothesized that AG accumulation in the inner ear catalyzes the formation of free-
radicals.3,4,7-9 When free-radical formation overwhelms the capacity of the intrinsic 
protective and repair systems, hair cells in the inner ear along with ancillary sensory cells 
and neurons undergo apoptotic cell death, resulting in irreversible hearing loss.6,9-13 
Chapter 2 explains this pathway in greater detail. 
There are several risk factors that appear to aggravate AG ototoxicity. High AG 
plasma concentrations and frequent or prolonged dosing may increase risk, yet 
monitoring of drug concentrations is not possible in most resource-limited settings. 
Further, the amount of AG that maintains therapeutic levels (to contribute meaningfully 
to multidrug therapy) but not supra-therapeutic (leading to hearing loss) has not been 
defined. The risk of hearing loss is impacted by human immunodeficiency virus (HIV) 
coinfection—up to 70% of South African MDR-TB patients are living with HIV—as a 
result of severe immunosuppression and the adverse effects of antiretroviral therapy 
(ART).14,15 Thus MDR-TB/HIV coinfected patients have a 22% greater risk of 
developing AG-induced hearing loss than non-HIV-infected MDR-TB patients.16 Both 
ART and anti-TB drugs may cause renal impairment, which hastens ototoxicity due to 
decreased renal excretion of AGs.17-21 Clinical manifestations of TB, such as malnutrition 
and severe, disseminated inflammation may be associated with increased incidence of 
hearing loss.22-28 Pre-existing hearing loss, prior use of ototoxic drugs for MDR-TB 
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treatment, comorbidities, advanced age, female gender, poverty, and substance use may 
increase the risk for subsequent hearing loss.29,30 Despite these known risks, there is no 
practical, cost-effective means to identify those at highest risk for developing hearing 
loss. Thus, practical tools to estimate the risk of AG-induced hearing loss are desperately 
needed to avoid this unnecessary adverse event and to guide clinical decision-making. 
 
PURPOSE AND STUDY AIMS 
The goal of this dissertation was to estimate the risk of AG-induced hearing loss 
for MDR-TB patients in South Africa. An ongoing cluster randomized clinical trial 
offered a unique opportunity to explore hearing loss and its determinants prospectively 
via a secondary data analysis.  
The specific aims of this study were: 
Aim 1: To explore the prognostic impact of cumulative AG exposure on AG-induced 
hearing loss in MDR-TB patients following initiation of injectable-containing multidrug 
therapy for MDR-TB 
Hypothesis: Patients within high cumulative AG exposure would have a shorter time 
to development of hearing loss than those with lower cumulative exposure. 
 
Aim 2: To develop a prediction model of AG-induced hearing loss in MDR-TB treatment 
Hypothesis: A model with potential predictors including cumulative (or weekly) AG 
exposure (daily dose x weekly frequency), HIV/ART status, CD4 count, presence of 
lung cavities, renal impairment, weight/BMI, serum albumin, pre-existing hearing 
loss, previous TB history, comorbidities, age, sex, poverty, and substance use can 





The parent study—A Nurse Case Management Intervention to Improve MDR-
TB/HIV Coinfection Outcomes with and without HIV Coinfection—is a NIAID-funded 
cluster randomized trial [R01 AI104488-01A1, PI: J. Farley]. The primary aim of the 
parent study is to determine the impact and cost effectiveness of a nurse case 
management (NCM) model on MDR-TB outcomes (i.e., cure, death, or default) in 
patients with MDR-TB with and without HIV coinfection in the Eastern Cape and 
KwaZulu-Natal provinces of South Africa.31,32 These two provinces have the highest 
MDR-TB incidence in the country.2 The trial includes 10 study sites (5 intervention and 5 
control sites) in which nurse case managers (NCMs) facilitate and coordinate treatment 
plans initiated by other clinicians for MDR-TB treatment. Participants included in this 
dissertation research were recruited into the parent study on initiation of MDR-TB 
treatment at the 10 study sites between November 2014 and June 2017 and were followed 
throughout the MDR-TB treatment course (~2 years), although the parent study is 
ongoing and actively recruiting patients. Participants in the parent study included those 
>13 years of age with microbiologically confirmed MDR-TB receiving standard of care 
for MDR-TB at a participating center. All eligible participants with known or suspected 
MDR-TB with rifampicin with/without isoniazid resistance from GeneXpert (cartridge-
based Xpert® MTB/RIF; Cepheid, Sunnyvale, CA, USA) should be started on 
standardized MDR-TB treatment within 5 days.2 Also, GeneXpert, LPA, and culture 
phenotype drug sensitivity tests should be followed to confirm either MDR-TB or XDR-
TB and to modify the MDR/XDR-TB treatment regimen depending upon the 
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susceptibility.2 If participants had been diagnosed with XDR-TB from drug sensitivity 
tests during the 6-months intensive phase, they were excluded from the study. All 
participating TB centers are public facilities and patients were generally poor or had 
exhausted medical aid available in the private sector. The centers do not collect racial 
statistics; however, the majority of individuals receiving care in these settings were black 
South Africans. All racial groups were screened for eligibility and had equal access to 
recruitment, and those who signed informed consent within seven days of treatment 
initiation were finally included. 
 
Standard of Care MDR-TB and Monthly Follow Up 
According to the South African National Department of Health guidelines, the 
standard MDR-TB regimen consists of at least 6 months of intensive phase treatment (= 
injectable phase) with one intramuscular injectable AG (e.g., kanamycin or amikacin) and 
four oral antimycobacterials (e.g., moxifloxacin, ethionamide, terizidone, and 
pyrazinamide).2 Dosing of AG is weight(kg)-based.2 Frequency of AG dosing varies 
from once-weekly to five times per week and is determined by physicians’ clinical 
judgement, based on patients’ pre-existing conditions in real settings. The clinical and 
laboratory evaluations are conducted at baseline and every month during the intensive 
phase, which includes microbiological assessment (i.e., sputum culture and microscopy), 
weight, BMI, vital signs, chest x-ray, albumin, full blood count, urea, electrolytes, vision 
testing, adverse drug reactions, and adherence.2 Audiometry is conducted at baseline and 
repeated monthly during the intensive phase or as symptoms warrant by an audiologist or 
providers.2 Although the WHO recommends therapeutic drug monitoring (TDM) for AG 
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treatment, it is not the standard of care according to the South African MDR-TB 
guidelines, and no clinical sites perform TDM due to limited MDR-TB treatment 
budgets.33 
 
Data Collection  
Data for the parent study were collected by NCMs at intervention sites or by 
research assistants (RA) at control sites. On the day of admission to the MDR-TB 
treatment program, patients were interviewed for sociodemographic data, medical 
history, and self-reported symptoms. Data were also collected through medical chart 
review and the National Health Laboratory System (NHLS) online laboratory portal. 
NCM intervention sites conducted additional patient level assessments through one or 
more interviews. All sites recorded weekly data from baseline to the end of the intensive 
phase of MDR-TB treatment, including patient vital signs, symptoms, medication 
changes, lab results, and treatment outcomes based on chart review and patient 
interviews. RAs at control sites collected baseline data from the medical records, NHLS 
online portal, and baseline patient interviews. All other follow-up data were abstracted 
from chart reviews and the NHLS portal. 
 
CONCEPTUAL FRAMEWORK 
The conceptual framework development process was guided by the OECD’s 
Guidance on Developing and Assessing the Completeness of Adverse Outcomes 
Pathways.34,35 The Adverse Outcome Pathway (AOP) is a model often used to predict the 
pharmacokinetic and pharmacodynamic responses of a drug and the relationship of these 
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to an adverse drug effect.36 The model consists of conceptual constructs and depicts 
existing knowledge of linkages between drug initiation, physiologic and molecular 
responses, followed by organ, then finally organism-level responses.36 Applying such an 
approach is helpful in hypothesizing relationships between different covariates when 
developing a prediction model associated with drug-induced adverse effects. Since AG-
induced hearing loss is influenced by pre-treatment and treatment-related conditions, 
relationships between risk factors were depicted through this model. See Chapter 2 for 




In 2016 WHO released new treatment guidelines offering for the first time a 
shortened MDR-TB treatment of 9-12 months.1 The regimen includes 7 drugs; AGs are 
given for at least 4 months.1 An AG-sparing regimen is reserved for those with 
substantial risk of hearing loss.1 Today that risk is based solely on clinical expertise 
without a tested and validated measure to support those decisions. This is the first study 
to develop and validate a hearing loss prediction model. The prediction model was 
developed by utilizing existing clinical data collected based upon South African national 
guidelines for MDR-TB management. Thus, additional lab tests or clinical evaluations 
would not be required to use the developed model. We expect that predicting hearing loss 
risk would reduce ototoxic drug use for those at highest risk and thereby reduce hearing 
loss. This is also one of the few studies to explore the impact of cumulative AG exposure 
using a reasonable surrogate measure of AG concentration on time to developing hearing 
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loss, adding richness to the understanding of risk of ototoxicity. The study addressed a 
critical need to estimate the risk for developing hearing loss in a low-resource setting 
where advanced screening for ototoxicity is not feasible. 
 
DISSERTATION ORGANIZATION 
 This dissertation is organized into seven chapters. Chapter 1 includes introductory 
and background materials, the purpose and specific aims, and the introduction of 
conceptual framework. Chapter 2 is a manuscript on the development of AOP conceptual 
model. Chapter 3 is a data-driven manuscript on the prevalence of pre-existing hearing 
loss and ototoxicity risk factors in MDR-TB patients. Chapter 4 is a published manuscript 
on increased risk of AG-induced hearing loss in MDR-TB patients with HIV coinfection 
through meta-analysis. Chapters 5 and 6 are data-driven manuscripts on the risk of AG-
induced hearing loss. Chapter 5 specifically explores the impact of cumulative AG 
exposure on AG-induced hearing loss outcome. Chapter 6 specifically develops the AG-
induced hearing loss prediction model. Finally, Chapter 7 provides a summary of 
findings, discusses further limitations of this study, and suggests implications for 
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Up to 69% of individuals with multidrug-resistant tuberculosis (MDR-TB) in sub-
Saharan Africa experience permanent hearing loss due to ototoxic effects of 
aminoglycosides (AGs)—injectable antibiotics for MDR-TB treatment. Despite our 
knowledge of the cellular mechanisms of ototoxicity and the global clinical experience 
among providers, AG-induced hearing loss has never been conceptually integrated or 
causally linked to MDR-TB patients’ pre-treatment health condition. Therefore, this 
study aimed to develop a framework that examines the relationships between pre-
treatment conditions and AG ototoxicity among MDR-TB-infected individuals in sub-
Saharan Africa.  
The adverse outcome pathway (AOP) approach was used to develop a framework 
linking key events (KEs) within a biological pathway that result in adverse outcomes 
(AO), which are associated with chemical perturbation of a well-defined molecular 
initiating event (MIE). This AOP describes pathways initiating from AG accumulation in 
hair cells, sound transducers of the inner ear immediately after intramuscular or systemic 
administration of AG. After administration, the drug catalyzes cellular oxidative stress 
due to overproduction of reactive oxygen species. Since oxidative stress inhibits 
mitochondrial protein synthesis, inner ear hair cells undergo apoptotic cell death—
resulting in irreversible hearing loss (AO). We identified the following pre-treatment 
conditions that worsen the causal linkage between MIE and AO: HIV, malnutrition, 
smoking, alcohol use, aging, and noise. The KEs are: (1) pre-existing hearing loss, 
nephrotoxicity, and hypoalbuminemia that catalyzes AG accumulation; (2) antioxidant 
deficiency and immunodeficiency that trigger oxidative stress pathways; and (3) co-
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administration of mitochondrial toxic drugs that hinder mitochondrial protein synthesis, 
causing apoptosis.  
This AOP clearly warrants the development of personalized interventions for 
patients undergoing MDR-TB treatment. Such interventions (i.e., choosing less ototoxic 
drugs, scheduling frequent monitoring, modifying nutritional status, avoiding poly-







Despite decades of effort to eradicate Mycobacterium tuberculosis (M.tb.), ~2.7 
million people have been diagnosed with tuberculosis (TB) in sub-Saharan Africa—26% 
of the total global incidence of TB in 2015.1 Particularly, multidrug-resistant TB (MDR-
TB) has emerged as a global epidemic and results in significant mortality.1 Because 
MDR-TB is resistant to the powerful first-line regimens (i.e., rifampicin and isoniazid), 
second-line antimicrobials are used to treat this infection. Up to now, second-line 
regimens for MDR-TB have consisted of one injectable drug along with four or more oral 
anti-TB drugs. The most widely used injectable drug is an aminoglycoside (AG) given 
during the first phase of treatment (at least 4 months).2 The U.S. Food and Drug 
Administration-approved AGs are gentamicin, tobramycin, amikacin, kanamycin, 
capreomycin, streptomycin, neomycin, and paromomycin for the treatment of serious 
infections caused by aerobic gram-negative bacilli; however, amikacin and kanamycin 
are the most frequently prescribed AGs globally for MDR-TB treatment recommended 
by the World Health Organization (WHO).2 
One of the most debilitating adverse outcomes from long-term use of AGs is 
ototoxicity. Up to 69% of individuals with MDR-TB infection in sub-Saharan Africa 
experience hearing loss.3 This incidence is almost 2-3 times higher than in high-resource 
countries, such as the U.S. (13%),4 the Netherlands (18%),5 and the U.K. (28%).6 AG 
ototoxicity appears to significantly contribute to hair cell injury, damaging both the 
cochlear and vestibular apparatus of the inner ear (Figure 1).7 Typical manifestations of 
cochleotoxicity consist of tinnitus and/or hearing loss, which begins with high-frequency 
hearing loss, which may or may not be clinically apparent, and often progresses to more 
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severe hearing loss even after discontinuation of AGs; while those of vestibulotoxicity 
include disequilibrium and dizziness with occasional nausea and vomiting.7-9 Vestibulo-
cochlear impairment, moreover, can be permanent. While hearing loss is one of the most 
common and debilitating adverse outcomes of AGs from MDR-TB treatment, strategies 
to reduce the risk such as selection of less ototoxic antibiotics or systematic monitoring of 
hearing loss are limited in many TB programs or clinical settings in sub-Saharan Africa 
due to cost and constraints on human resources for health care. Compared to less-toxic 
antibiotics, AGs are extremely inexpensive relative to the high potency they offer.7,10,11 
Financial considerations may, in part, explain the higher incidence of AG-induced 
hearing loss in resource-limited countries compared to high-resource countries. However, 
HIV coinfection, which is substantially more common in many low resource settings may 
also play a major role.3 Presently, there are no practical and cost-effective tools to 
identify those at highest risk for developing hearing loss from AG treatment. To avoid the 
unnecessary occurrence of this adverse outcome and to guide clinical decision-making, it 
is critical to assess individuals’ potential risk for ototoxicity before initiation of MDR-TB 
regimen.  
The Adverse Outcome Pathway (AOP) is a conceptual framework representing a 
set of plausible connections from an initiating event to an adverse outcome considered 
relevant in risk assessment in predictive toxicology.12,13 The framework consists of 
conceptual constructs and depicts existing knowledge concerning the predictive and/or 
causal linkages between drug initiation, physiological and molecular responses, and 
organ and organism-level responses.12 Since the AOP includes integrated sequential 
pathways, it is often used to develop integrated tools for predictive toxicology, regulatory 
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toxicity testing, and risk assessment.12,14 Despite examination of the mechanisms of AG-
induced hearing loss at a cellular level, AG-induced hearing loss has never been 
conceptually integrated or causally linked to MDR-TB patients’ pre-treatment health 
condition, which may play a pivotal role in aggravating the ototoxicity pathway. 
Therefore, this study aimed to develop a framework that examines the relationships 
between pre-treatment conditions and AG ototoxicity among MDR-TB-infected 
individuals in sub-Saharan Africa.  
 
MATERIAL AND METHODS 
AOP Development  
The conceptual framework development process was guided by the Organization 
for Economic Co-operation and Development’s (OECD) Guidance on Developing and 
Assessing the Completeness of Adverse Outcomes Pathways.12,15 AOP methodology 
shares a common schematic representation consisting of a molecular initiating event 
(MIE), intermediate key events (KE), and an adverse outcome.12 MIE is defined as a 
chemical interaction with a biological target.12 In this study, the MIE refers to AG 
molecular accumulation in the interstitium of hair cells in the inner ear that initiates the 
toxicity pathway. The MIE is associated with a set of potential apical hazard endpoints,12 
but the AG-induced sensori-neural hearing loss (SNHL) is the apical adverse outcome of 
interest in this pathway. The MIE and adverse outcomes are causally linked with a series 
of KEs that are direct chemical effects or responses initiated from or prior to the target 
sites through the cellular or higher levels of biological organization, scientifically proven 
by in vitro and/or ex vivo studies.12 In this pathway, three key events were identified: (1) 
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KE1—prerequisite events that directly impact MIE highlighted in orange arrows, (2) KE 
2—prerequisite events that impact initial cellular responses highlighted in green arrows, 
and (3) KE 3—prerequisite events that impact the latter cellular responses highlighted in 
a purple arrow in the proposed AOP framework (Figure 3). To evaluate whether scientific 
qualitative and quantitative data precisely support a causal relationship between the 
observed outcomes and a given chemical, Weight-of-Evidence supporting the AOP was 
assessed by modified Bradford Hill Criteria per OECD guidelines.12,16 Institutional 
Review Board approval was not required for this study as human subjects were not 
involved in the research. 
 
RESULTS 
3.1. MDR-TB treatment  
Second-line injectable AGs recommended by the WHO for MDR-TB treatment 
include amikacin, kanamycin and streptomycin;2 however, streptomycin is no longer 
considered a second-line agent because it was previously widely used for TB retreatment, 
and MDR-TB strains are more likely to be resistant to streptomycin than the other 
aminoglycosides.2 The selection of amikacin versus kanamycin for providers and 
organizations is determined by the likelihood of effectiveness,  availability, and cost.2 
 
3.2. AG – Mechanism of Action  
AGs are highly potent and broad-spectrum bactericidal agents used for the 
treatment of serious gram-negative bacteria or mycobacteria including M.tb.17 Their 
primary site of action is the 30S ribosomal subunit.17,18 To reach the site, molecules cross 
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the bacterial cell wall through active transport into the cell cytosol; thereby, they inhibit 
bacterial protein synthesis that results from misreading of the genetic code.17-20 AGs have 
very poor oral bioavailability because they are highly polar cations. Only 0.3–1.5% of an 
orally or rectally administered dose of aminoglycoside reaches the systemic circulation 
and then appears in the urine.19 Thus the route of AG administration is intravenous (IV), 
intramuscular (IM), intraosseous (IH), topical (cream/ointment), and ophthalmic. AGs are 
water-soluble and freely filtered across the glomerulus; almost all of the drug is then 
excreted.18,21 
 
3.3. MIE – Molecular interactions  
Although AGs preferentially target the bacterial ribosome, the inner ear and 
kidney are known to receive collateral damage.7 The mechanisms of AG uptake into 
sensory hair cells and renal epithelial cells increase the susceptibility to both ototoxicity 
and nephrotoxicity, which can be explained by the physiological similarities between the 
cochlea and kidneys in terms of active transport of fluid and electrolytes to achieve iso-
osmotic balance.8 The accumulation of AGs appears to be dose- and duration-dependent; 
uptake into the inner ear occurs rapidly and exposures persist for longer than other 
organs. In animal studies, AGs enter the cochlea within a few minutes and hair cells 
within 3 hours after systemic administration.22-24 AG concentrations in the inner ear are 
higher than plasma concentrations because the half-life of AGs in perilymph fluid are 10 
to 15 times longer than in serum.25 The receptor-mediated endocytosis at the apical 
surface of hair cells in the cochlea plays a role in AG uptake—AG molecules are found in 
vesicles beneath the hair cells.26 AGs are also taken up into the renal epithelial cell line 
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via an endocytotic process, which explains the nephrotoxicity after glomerular filtration 
of the agent.26 Along with endocytosis, the presence of several ion channels at the hair 
cells, such as the mechanoelectrical transducer (MET) cation channel quickens AG 
accumulation. The MET channel increases the potential differences between extracellular 
fluid and cytoplasm and functions like a one-way valve, promoting the likelihood of 
cellular uptake and accumulation of cationic AGs in the cytoplasm in the hair cells and 
renal cells.27-29 Consequently, AG molecules accumulate rapidly and are eliminated 
slowly from the inner ear; thus, hair cells are more susceptible to AG-related processes 
than other cell types.  
 
3.4. Cellular and Organ Responses.  
Reactive oxygen species (ROS) are byproducts of normal mitochondrial 
metabolism; ROS contribute to organ homeostasis by controlling normal cell growth, 
differentiation, development, and death.30,31 TB infection induces ROS production 
through activation of phagocytes—a part of host defense mechanism against M.tb.32 
Further, the AG molecules that enter hair cells readily bind to cytosolic proteins, 
specifically calreticulin, which plays a role in Ca2+ homeostasis.33 AG binding to 
calreticulin dysregulates cytosolic Ca2+ concentration,34 which in turn induces 
mitochondrial Ca2+ overload, producing cytoplasmic ROS and causing mitochondrial 
oxidation.35 In addition, since AGs act as iron chelators, the formation of redox-active 
iron-AG complexes catalyzes oxygen-derived free radicals.36,37 Thus, ROS over-
production with exhaustion of the capacity of the intrinsic protective and repair system 
results in oxidative stress.31,38 Moreover, the Transient Receptor Potential (TRP) cation 
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channels—particularly the subfamily TRPA1-containing pore helices—are located in the 
outer hair cells. The TRPA1 channels function as inflammatory, irritant, and oxidative 
stress sensors.39,40 Activation of TRPA1 channels resulting from oxidative stress or noise-
exposure, enlarges the pore diameter to dimensions larger than AG molecules, thereby 
facilitating AG uptake into the hair cell41. Oxidative stress contributes to mitochondrial 
depolarization and dysfunction, and mitochondrial protein synthesis inhibition, which in 
turn activates programmed cell death-signaling pathways, such as mitogen-activated 
protein kinases (MAPK).38,42-45 Consequently, hair cells along with ancillary sensory cells 
and neurons—mainly the cochlear portion of the auditory nerve—undergo apoptotic cell 
death, resulting in irreversible SNHL.36,37,46,47  
 
3.5. Key event 1: Prerequisite events that directly impact MIE 
3.5.1. Nephrotoxicity  
Individuals with renal impairment may experience decreased AG clearance and 
increased AG accumulation, as AGs are mostly eliminated by glomerular filtration. As a 
result, sustained and excessive peak serum concentrations are considered risk factors for 
hearing loss. AGs are also nephrotoxic; renal function at treatment initiation directly 
influences the level of AG accumulation in hair cells. Thus ototoxicity can be caused by 
AG toxic levels or renal impairment, which leads to reduced AG clearance and more drug 
accumulation.7 Comorbid conditions that influence renal function directly or indirectly 
through chronic use of nephrotoxic drugs would induce AG ototoxicity. A common 
example in sub-Saharan Africa is HIV coinfection. Renal complications of HIV infection 
are common and include proteinuria, interstitial nephritis, renal tubular damage, and 
 
24 
nephrolithiasis; HIV-associated nephropathy—coupled with the use of nephrotoxic 
antiretroviral drugs such as Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in 
particular—lead to excessive AG accumulation.48-52 
 
3.5.2. Pre-existing hearing loss.  
Pre-existing hearing loss at MDR-TB diagnosis commonly originates from 
previous exposure to ototoxic drugs, noise exposure, advanced age, or idiopathic 
SNHL.53 Particularly, because acoustic stimuli increase permeability of cation channels 
such as MET and TRP, the noise exposure also increases the AG uptake and directly 
accelerates intracellular accumulation of AGs within hair cells.54-56 Age-related hearing 
loss, or presbycusis, caused by the degeneration of cochlear cells is also a major cause of 
pre-existing hearing loss.57 As tissue ages, the hair cells also undergo progressive 
oxidative mitochondrial DNA damage modified by excessive ROS generation and 
chronic inflammatory damage due to immunosenescence.58-62 This results in auditory 
sensory cell degeneration. Further, HIV can cause pre-existing hearing loss directly and 
indirectly. A primary HIV infection in either the central nervous system or peripheral 
auditory nerve causes SNHL, although the exact mechanism of nervous destruction is 
still unclear.63 A human study did not find histopathologic changes using electron 
microscopy supporting that HIV directly damages the cochlear end organs.64 However, a 
recent observational study found that HIV-infected adults had significantly poorer 
hearing threshold in both low and high frequencies than HIV-uninfected adults.65 
Opportunistic infections are one of the common indirect causes of pre-existing hearing 
loss. The most frequent otologic opportunistic infections found in HIV-infected 
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individuals include seborrheic dermatitis of the external ear, otitis externa with 
otomycosis, and serous otitis media.66,67 Because these infections are mostly caused by 
community-acquired organisms, such as Pseudomonas aeruginosa, Aspergillus, 
fumigatus, Candida albicans in outer ear and Streptococcus pneumoniae, Hemophilus 
influenzae and Moraxella catarrhalis in middle ear,66,67 frequently recurrent acute or 
chronic ear infections lead to conductive hearing loss before or during AG treatment.68 
Due to lack of trained healthcare providers or devices, it is difficult to confirm 
SNHL by differentiating it from conductive hearing loss by comprehensive audiological 
assessment, including otoscopy, tympanometry, and air-bone conduction audiometry in 
most countries in sub-Saharan Africa.3 Thus, underdiagnosed ear infections may 
masquerade as AG-induced hearing loss, and undertreated ear infections aggravate 
oxidative stress from altered metabolic pathways.68 While otosyphilis is a rare 
complication of syphilis, it is not an uncommon cause of inner ear infection in people 
living with HIV. A clinical manifestation of acute syphilis with cochleovestibular 
involvement includes sudden SNHL;69 otosyphilis amplifies oxidative stress but thereby 
may magnify symptoms of AG-induced hearing loss. Otosyphilis seems to lead to 
endolymphatic hydrops in the cochlea or atrophy of the organ of Corti, spiral ganglion, 
and stria vascularis (Figure 2),70 which may reduce endocochlear potential, resulting in 
cochlear sensitivity to sound. Also, because HIV drugs, particularly NRTIs—including 
zidovudine, didanosine, stavudine, and lamivudine—have ototoxic potential via their 
effect of reducing mitochondrial DNA content, the use of NRTIs prior to MDR-TB 
treatment may potentiate the ototoxic effect of AGs.71,72 This association has been 
specified in key event 3 (Figure 3).   
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3.5.3. Hypoalbuminemia.  
Malnutrition—an insufficiency or unbalance of nutrition—is a significant health 
issue in people living with MDR-TB with or without HIV and is more prominent in 
resource-limited environments due to food insecurity.73-77 Malnutrition is a result of a 
deficiency of both macronutrients (nutrients that provide calories or energy, including 
carbohydrates, proteins, and fat) and micronutrients (i.e., vitamins and minerals), vital 
dietary components necessary for physical and mental development, disease prevention, 
and well-being.78,79 Most individuals with active TB are in a catabolic state and 
experience weight loss and signs of vitamin and mineral deficiencies.80 Protein-energy 
malnutrition (PEM) caused by insufficient intake of protein and calories is more 
prominent among TB and HIV coinfected patients and is worsened by TB-induced 
muscle wasting.78,81-84 In the case of PEM, albumin synthesis is impaired, leading to low 
serum albumin concentration (hypoalbuminemia).84,85 Since albumin plays a pivotal role 
in maintaining colloid oncotic pressure, hypoalbuminemia results in an abnormal increase 
of inner ear fluid volume by diminishing the osmotic gradient,86,87 accelerating AG 
accumulation because AGs are water-soluble.21 
 
3.6. Key event 2: Prerequisite events that impact initial cellular responses 
3.6.1. Immunodeficiency  
HIV infection weakens the human immune system by killing T-helper cells, 
macrophages, and dendritic cells, thus causing immunodeficiency.88 HIV infection leads 
to chronic activation of nuclear factor (NF)-κB—a master regulator of pro-inflammatory 
genes, which produces pro-inflammatory cytokines, such as interleukin 1 (IL-1), IL-6, 
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and tumor necrosis factor-alpha (TNF-α).89 Soon after the secretion of pro-inflammatory 
cytokines, neutrophils and other immune cells migrate to the infection site in various cell 
types depending on opportunistic infections including TB, where they ingest bacteria and 
kill them by releasing ROS, which causes oxidative stress and mitochondrial DNA 
damage.32 Further, HIV-infected individuals with advanced disease have increased levels 
of oxidative DNA damage biomarkers (i.e., 7,8-dihydro-8-oxoguanine) in CD4+ T cells 
and show declines in DNA glycosylase activity for the repair of oxidative base lesions in 
these cells.90 In addition, the number of CD4+ cells is positively associated with the 
levels of intracellular concentration of antioxidants, especially glutathione.91,92 In 
particular, people living with HIV who are not taking ART may have increased risk of 
AG ototoxicity since ART restores the numbers of CD4+ T-cells while it augments the 
imbalanced redox status.93 
 
3.6.2. Antioxidant deficiency.  
Antioxidant deficiency causes hair cells to be more vulnerable to oxidative stress, 
which contributes to apoptotic hair cell death. For example, the presence of glutathione—
an endogenous antioxidant resulting in detoxification of xenobiotics and protection 
against ROS94—protects the hair cells against oxidative stress.95,96 Dietary nutrient-based 
antioxidant supplementation, including vitamin A, β-carotene (one of the provitamin A 
carotenoids), vitamin C, and vitamin E, significantly attenuated outer hair cell damage, as 
they have anti-inflammatory properties.46,97,98 Albumin also has antioxidant properties 
through its multiple binding sites and capacity to trap free radicals.99 Thus, 
hypoalbuminemia also worsens antioxidant deficiency. Antioxidant deficiency is caused 
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not only by poor intake of dietary sources but also by smoking, alcohol consumption, and 
aging, which inhibit synthesis of antioxidant enzymes and reduce antioxidant 
concentrations.100-106  
 
3.7. Key Event 3: Prerequisite events that impact latter cellular responses  
3.7.1. Mitochondrial toxicity  
Use of mitochondrial toxic drugs may potentially worsen AG ototoxicity. NRTIs 
can inhibit human DNA polymerases, including gamma polymerase—important to 
mtDNA replication—that may damage mtDNA; key event 3 may also directly activate 
the MAPK pathway.107-109 In particular, Tenofovir Disoproxil Fumarate (TDF) is one of 
the most common choices of NRTI; however, it targets the mitochondria of both hair 
cells and renal proximal tubules, increasing the risk of ototoxicity, as does key event 1. 
Since the combination of two NRTIs constitutes the backbone of ART regimens,110 
individuals on both NRTIs and AGs are at higher risk of apoptotic hair cell death. 
 
3.8. Assessment and Confidence Testing 
Bradford Hill Criteria consist of 6 items: evaluating the concordance, strength, 
consistency, and specificity of associations between conceptual constructs within AOP, 
as well as the biological plausibility and coherence of experimental evidence.12 To 
achieve confidence in the proposed AOP, 5 items were addressed to evaluate the 





3.8.1. Assessment of the AOP According to the Bradford Hill Criteria 16  
3.8.1.1. Concordance of dose-response relationships.  
AG-induced ototoxicity occurs in basal outer hair cells and then extends to inner 
hair cells and further apical outer hair cells with an increasingly cumulative AG dose.8 
Many classic laboratory animal studies have revealed that AG-induced vestibulocochlear 
toxicity ranges over duration and levels of exposure.111-114 Cochleotoxicity was tested in 
response to a range of amikacin doses in adult rats for 5 consecutive days.113 Hair-
cell stereocilia degeneration occurred in the high-dose group (i.e., 600-1000 mg/day): the 
low-dose group did not develop cochlear abnormalities (i.e., 200 mg/day).113 In addition, 
the pattern of hair cell degeneration—most severe in the basal regions of the cochlea with 
decreasing gradient towards the apex—was dependent on the administered dose of 
amikacin.113 Streptomycin also causes vestibulotoxicity in a dose-response manner. 
Vestibular disturbance was observed in cats 12-19 days after receiving a low-dose of 
streptomycin (100-200 mg/kg daily); however, the cats that received 400 mg/kg became 
ataxic shortly after administration of the first dose, which persisted for almost 24 
hours.114 
 
3.8.1.2. Temporal concordance among the key events and adverse outcome  
The temporal relationship among the three key events are dependent on the pre-
treatment conditions that are present. Each pre-treatment factor may influence multiple 
key events that occur in sequential order. Prerequisite events are mediated by the 
presence of pre-treatment factors with or without exposure to toxicants, which precede 
AG accumulation in the interstitium of hair cells (MIE). Since AG accumulation is an 
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essential prerequisite for apoptosis of hair cells, the temporal sequence from pre-
treatment conditions through AG-induced SNHL is well supported.   
 
3.8.1.3. Strength, consistency, and specificity of association of adverse outcome and 
initiating event  
We explained that AG-induced SNHL is caused by the oxidative stress that results 
from excessive AG accumulation in the hair cells (MIE). The causality of this pathway 
can be inversely proven by the following experimental and clinical studies that tested 
protective effects by targeting various steps of the ototoxic cascades: 
(1) Reducing AG uptake: Evidence for the molecular identity of the MET channel 
strongly supports the potential modification of MET channel permeability, reducing 
AG uptake.27,115,116 
(2) Iron chelators and antioxidants as ROS scavengers: Attenuated hair cell apoptosis 
capacity have been confirmed by administration of iron chelators or antioxidative 
agents, such as salicylates,117,118 deferoxamine,119 N-Acetylcysteine,97,120 D-
Methionine,121,122 α-lipoic acid,123 ascorbic acid (vitamin C),98,124 α-tocopherol 
(vitamin E),98,125 magnesium,98 and misoprostol.126 
(3) Inhibiting the MAPK pathway: Inhibition of the MAPK pathway by application of 
D-JNKI-1,127 CEP 11004,128 and estradiol129 prior to AG administration result in 





3.8.1.4. Biological plausibility, coherence, and consistency of the experimental 
evidence  
The biological plausibility, coherence, consistency, and strength of the 
experimental evidence that supports the proposed AOP is detailed in Table 1. 
 
3.8.1.5. Alternative mechanism(s) that logically present themselves and the extent to 
which they may distract from the postulated AOP.  
The mechanism of AG-induced ototoxicity with hearing loss is less 
understood. However, one potential alternative hypothesis is the presence of N-methyl-D-
aspartate (NMDA) at the synapse between cochlear hair cells and spiral ganglion neural 
afferents.130,131 At NMDA receptors, AG mimics the positive modulation of polyamines, 
potentially leading to excitotoxic damage at the hair cell-afferent nerve synapses.132 Since 
hair cell apoptosis resulting from ROS overproduction is a significant modifiable 
pathogenesis of AG ototoxicity, our AOP did not include mechanisms of NMDA 
receptors; thereby, separate AOP could depict such alternative mechanism.   
 
3.8.1.6. Uncertainties, inconsistencies and data gaps  
Assessments of human tissue from patients with MDR-TB, with or without HIV 
coinfection, for evidence of AG-related pathophysiology have not been conducted for 
obvious ethical reasons. Although AG ototoxicity has been comprehensively studied, the 
major events within the proposed AOP have been causally explained by healthy 
preclinical animal models, while AG has mostly been administered to those with severe 
infections in clinical settings. However, a recent animal study induced systemic host-
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mediated inflammatory conditions by injecting lipopolysaccharide (LPS), an important 
component of bacterial endotoxin, to experimental mice.133,134 While LPS alone did not 
affect hearing, mice that received LPS prior to ototoxic agents had worse hearing loss 
than those that did not receive LPS pretreatment resulting from accelerated AG 
uptake.133,134 Such animal studies are unable to fill the gap entirely, but evidence from 
preclinical work supports the hypothesis that persistent inflammation contributes to AG 
ototoxicity.   
 
3.8.2. Confidence in the AOP  
3.8.2.1. How well-characterized is the AOP?  
AG-induced ototoxicity is a well-understood phenomenon. We adapted the 
Mitochondrial Free Radical Theory of Aging to explain the relationship between AG 
molecules and active free radicals, which are generally produced in the organism at the 
cellular level.106 Such relationship is supported by experimental data, as specified in 
Table 1.  
 
3.8.2.2. How well are the initiating and other key events causally linked to the 
outcome? 
Multiple experiments have demonstrated that AGs are causally linked to SNHL in 
a dose-dependent way in both animals and humans. Evidence is strong to support a causal 





3.8.2.3. What are the limitations in the evidence in support of the AOP?  
There are unmeasurable variables that may confound the relationship outlined in 
the AOP, such as known and unknown genetic mutations or additional confounders we 
may not have thought of. Specifically, mtDNA mutation is a risk factor that may be 
considered as one of the pre-treatment conditions as several genetic mutations also 
increase the susceptibility to ototoxicity. The mitochondrial rRNA mutation, particularly 
in the 12S rRNA gene, such as A1555G (most common), C1494T, T1095C, T1291C, 
961delT+C(n), and A827G, among others, increase the structural similarity of human 
mitochondrial ribosomal RNA (rRNA) to bacterial 16S rRNA.135-137 As a result, mutated 
mitochondrial ribosomes in the cochlea become target-binding sites for AGs,138,139 and 
AGs lead to misreading of the genetic code along with perturbation of ribosomal 
translation.136,137 This causes mitochondrial ribosomal damage and further cytotoxicity as 
it directly activates the MAPK pathway with apoptosis.127,140-142 The most common type 
of mitochondrial A1555G gene mutation is most prevalent in Europeans (0.19%)143,144 
but not in sub-Saharan Africans, where the prevalence of the mutation is extremely low 
(0% to 0.09%).145-148 As a result, mtDNA mutation was not addressed and 
generalizability is limited because this model targets evidence obtained within the sub-
Saharan African MDR-TB populations and in resource-limited settings. To date, 







3.8.2.4. Is the AOP specific to certain tissues, life stages/age classes?  
Advanced age may increase the risk for AG ototoxicity. Presbycusis is difficult to 
characterize because of genetic and environmental influences, and because of its 
complexity of structural changes confounded by various medical, psychological, and 
pharmacologic factors.149 However, presbycusis is also caused by apoptotic hair cell 
death resulting from excessive oxidative cellular stress, which in turn stimulates the 
MAPK pathway. Age-dependent renal function is also closely related to this pathway 
because AG elimination is mostly completed through renal clearance. Age-related 
reduction in creatinine clearance among elderly populations increase the risk of 
ototoxicity.150,151 The glomerular filtration rate is low at birth, reaches about adult levels 
by the end of the second year of life, and declines after the fourth decade.151 Thus, 
infants, young children, and the elderly are more susceptible to AG-induced SNHL, but 
this AOP is developed targeting adult populations.  
 
3.8.2.5. Are the initiating and key events expected to be conserved across taxa? 
Experimental studies in multiple types of animals across species, including 
zebrafishes,22,152 bullfrogs,24 chicks,24,26 mice,24,115,133,134,153,154 rats,113,120,155 turtles,27 
cats,114 and guinea pigs23,24,54,95,111,122,156,157—all show evidence in support of this 
pathway. Human autopsies have also shown this relationship.20,158 
 
DISCUSSION 
Overall, AG ototoxicity caused by apoptotic hair cell death is a complex process, 
although our understanding of it has increased in recent years. Based on the modified 
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Bradford Hill Criteria, we believe this AOP provides critical, evidence-based insights 
into AG-induced hearing loss. AG-induced hearing loss prevention in TB programs is a 
real challenge due to complicated clinical conditions, and the causal relationship between 
treatment and adverse outcomes is often difficult or impossible to determine definitively. 
Although maintaining therapeutic levels, but not supra-therapeutic, AG concentration 
aids in hearing loss prevention and cure of MDR-TB, frequent therapeutic drug 
monitoring (TDM) is impractical in most resource-limited settings. While the causative 
genomic variants have been studied to determine the phenotype-genotype correlations 
with AG-induced hearing loss,159 genetic services are not available in many clinical 
settings as a screening tool. As there are no practical screening tools to aid in the 
prevention of ototoxicity, knowing the mechanism of AG ototoxicity and its linkage with 
pre-treatment physical conditions associated with MDR-TB is critical for designing 
strategies to prevent AG-induced irreversible SNHL.  
This is the first attempt to develop an AOP framework that outlines the apoptotic 
cascade in AG toxicity. This AOP framework will broaden our understanding of the 
complexity of AG-induced hearing loss and interactive health conditions in individuals 
before and after AG exposure. Such schematic representations can be used as a tool for 
healthcare providers to make clinical decisions, particularly in developing personalized 
interventions, such as choosing less ototoxic drugs or scheduling more frequent toxicity 
monitoring. The proposed AOP can be favorably applied not only in clinical practice but 
also widely in public health research as it is helpful in hypothesizing the relationships 
between different covariates associated with drug-induced adverse outcomes. Examples 
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of clinical implications and recommendations based on the key elements and contributors 
to hearing loss are summarized in Table 2.  
Since AG ototoxicity is concentration-dependent, AG dose and use should be 
tightly regulated in inpatient settings, with serial measurement of creatinine and 
estimation of creatinine clearance coupled with TDM, which is a measurement of 
aminoglycoside peaks and troughs, and adjustment of dosing to remain in the targeted 
therapeutic ranges.18 In outpatient settings or home-visiting programs, however, 
optimizing AG dosing is considerably challenging because TDM is unavailable in real 
time. As a result, detection of ototoxicity could be delayed because cochlear damage is 
initially asymptomatic. Thus, future research should consider the development of a 
surrogate measure of AG concentration without laboratory testing and examine its 
practical feasibility in resource-limited environments.  
Although the proposed AOP is theoretically and practically useful, application is 
limited to MDR-TB treatment in resource-limited settings particularly in sub-Saharan 
Africa because this study does not account for genetic variance. Furthermore, we 
acknowledge that the proposed AOP oversimplifies the complex pharmacopathological 
and pharmacotoxicological process, which did not capture all potential mechanisms. 
Since this AOP was developed based on currently available scientific evidence, it must be 
considered an open and flexible framework that requires continuous refinement. There is 
a need for well-designed and adequately powered observational studies to identify the 
risk factors for AG ototoxicity that are present at MDR-TB treatment initiation and 
during treatment, through thorough history-taking and frequent hearing screening. Since 
polypharmacy is common among people with MDR-TB and HIV,160 future studies may 
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be helpful in elucidating drug-drug interactions and drug-gene interactions with AG and 
would be a good scientific addition to understanding and prevention of AG-induced 
hearing loss. Continuous attention to the prevention of AG-induced hearing loss during 




Table 1. Summary of Information on the Key Events of the AOP 
Key Events Description of Events Experimental Support and References 
MIE: AG 
accumulation in 
the inner ear hair 
cell 
The receptor-mediated 
endocytosis and presence of 
MET cation channel lead to 
rapid accumulation and slow 
elimination of AG in the inner 
ear 
(1) KM was taken up into sensory hair cells via receptor-mediated endocytosis at their apical 
surfaces because AG molecules are found in vesicles beneath the hair cells from White Leghorn 
chicks, confirmed by immuno-gold electron microscopy.26,161 
(2) MET channels on hair cell functions as open transducer channels that is the main route for 
aminoglycoside entry. AGs functioned as voltage-dependent MET channel blockers that also 
rapidly permeate through MET channels into hair cells, which was found in bullfrog model,162 
turtle model,27 and mouse model.29 The AG molecules enter the channel and block the ion-
conducting pathway, thus such blockage increases voltage. Increased AG entry through the 
channel pore into the hair cell due to the large electrical driving force also increases the affinity 








and pre-existing hearing loss 
(KE1-3) accelerate AG 
accumulation in the 
interstitium of hair cell 
(1) TDF is mitochondrial toxic, increasing number of abnormal mitochondria including 
irregular mitochondrial shape, and sparse, fragmented cristae. Abnormal proximal tubule 
functioning and decreased GFR occurred in patients who had been taking TDF in multiple 
studies.48-52 
(2) The albumin-like proteins, including albumin, IgG, IgA, transferrin, antitrypsin, and 
haptoglobin were the major protein compositions of luminal fluid in inner ear.86,87 Among 
patients (n = 11) with enlarged vestibular aqueducts, patients with recent hearing loss and 
increased volume of luminal fluid showed a significantly decreased proportion of the albumin-
like proteins in the interstitial space.86 
(3) Pre-existing hearing loss includes mainly noise-induced and age-related hearing loss. 
Histological evaluation using mice (n=22), received repetitive exposure the acoustic stimuli 
(~4.5 kHz with 120.5 dB sound pressure level), showed significant structural hair cell damage.56  
It has been found that atrophy of the stria vascularis of cochlear duct was observed in older 
mice (older than 12 months at least), and that lipofuscin (aging associated pigment granules) 
accumulation in inner and outer hair cells of the mice were also found from the same age.62 This 
structural change is accelerated by the age-related dysfunctions of the systemic immune system 
accelerated, worsening presbycusis.58-62 
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Immunodeficiency (KE2-1)  
and antioxidant deficiency 
(KE2-2) trigger cellular 
oxidative stress  
(1) In comparison between 8 HIV-infected patients (mean CD4+ T-cells count = 280 × 106/L), 7 
AIDS patients (mean CD4+ T-cells count = 45 × 106/L), AIDS patients had increased levels of 
7,8-dihydro-8-oxoguanine in CD4+ T cells and marked declines in DNA glycosylase activity 
for the repair of oxidative base lesions in these cells.90 People living with HIV showed elevated 
pro-inflammatory cytokines, including interleukin 2 (IL-2), IL-6, and tumor necrosis factor-
alpha (TNF-α) and biomarkers associated with inflammation and coagulation, including C-
reactive protein (CRP) and D-dimer due to chronic inflammation and immune activation.163-166 
In cross-sectional human study, the level of lipid peroxidation (LPO) and glutathione were used 
as a means of determining oxidative stress. The mean LPO levels were significantly higher in 
HIV-infected patients (n=100; mean= 0.7 ± 0.1 μmol/ml) as compared to healthy controls 
(n=30; mean= 0.3 ± 0.1 μmol/ml). The mean glutathione level in HIV-infected patients 
(0.06 ± 0.01 μmol/ml) was significantly lower in compared to healthy controls 
(0.09 ± 0.01 μmol/ml).91,92 
(2) A human study found that compare to younger control subjects, elderly subjects had 
significantly lower level of glutathione (2.08 ± 0.12 vs. 1.12 ± 0.18 mmol/L RBCs; P < 0.05); 
glutathione synthesis rates (1.73 ± 0.16 vs. 0.55 ± 0.12 mmol/L RBCs per day; P < 0.01); and 
higher plasma oxidative stress (304 ± 16 vs. 346 ± 20 Carratelli units; P < 0.05) 
simultaneously.167 This indicates that glutathione deficiency in elderly humans resulted from a 






Mitochondrial toxicity (KE3) 
worsens inhibition of 
mitochondrial protein 
synthesis of hair cells 
Since reductions in mitochondrial DNA content induced by NRTIs, significantly more HIV-
infected patients had or developed persistent hearing loss with/without tinnitus during follow-
up.107-109 After short-term exposure to AZT, d4T, ddC, ddI, and FLT (6-72 hours), mtDNA copy 
numbers were markedly decreased because the NRTIs inhibit mtDNA replication.168 
Upregulation of glutathione S-transferase 4 expression were significantly increased, which 
suggests that ROS defense mechanisms likely to be induced by NRTI administration due to 
mtDNA intoxication.168 
AO: SNHL When programmed cell death-
signaling pathways has been 
activated, hair cells, ancillary 
sensory cells, and neurons 
undergo apoptotic cell death, 
resulting in irreversible SNHL 
ROS formation through ototoxicants, including gentamicin and kanamycin, in cochlear tissues 
of was directly observed in guinea pig by electron paramagnetic resonance spectrometry46 and 
in chick by using dichlorofluorescin.47   When chicks and mouse cochlear and vestibular hair 
cells were exposed to gentamicin, the incorporation of methionine-free medium over 24 hours 
was reduced by 30–60% compared to control conditions observed by fluorescence 
microscopy.169 This indicates gentamicin inhibited the medium uptake into hair cells by 
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inhibiting protein synthesis in hair cells and activate a c-Jun N-terminal kinase (JNK) pathway 
as JNKs activate apoptotic signaling.169 
Abbreviations: MIE= molecular initiating event; KE= key event; AO= adverse outcome; HIV= human immunodeficiency virus;  CD4= cluster of differentiation 
4; SNHL= sensorineural hearing loss; MET= mechanoelectrical transducer; NRTI= Nucleoside Reverse Transcriptase Inhibitor; KM= kanamycin; TDF= 
Tenofovir disoproxil Fumarate; ROS= reactive oxygen species; AZT= zidovudine (3'-Azido-3'-deoxythymidine); d4T= stavudine (2’,3’-didehydro-2’,3’-
deoxythymidine); ddC= zalcitabine (2’,3’-dideoxycytidine); ddI= didanosine (2’,3’-dideoxyinosine); FLT= alovudine (3’-deoxy-3’-fluorothymidine) 
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Table 2. AOP implications and recommendations in MDR-TB treatment 
Pre-treatment conditions or 
prerequisite events 
Recommendations 
Untreated HIV and/or NRTI use • Monitor CD4+ T-cell count and viral load. 
• Consider NRTI-sparing antiretroviral regimen.  
• Monitor oto- and nephro-toxicity more closely. 
Renal insufficiency • Monitor renal function more closely including BUN, creatinine (serum or urine), and 
creatinine clearance, etc.  





• Provide dietary counseling. 
• Consider macro- and micronutrient supplementation. 
• Monitor serum albumin level more closely. 
Pre-existing SNHL • Conduct comprehensive audiological evaluations including occupational/recreational noise 
exposure, family history of ototoxicity or hearing loss, audiometry, tympanometry, and 
otoscopy prior to AG initiation. 
• If moderate to severe hearing loss screened consider AG-sparing MDR-TB regimen or more 
frequent systematic audiological evaluations should be followed. 
Substance abuse • Provide alcoholism and smoking cessation counseling and rehabilitation  
Abbreviations: AG= aminoglycoside; CD4= cluster of differentiation 4; HIV= human immunodeficiency virus; SNHL= sensorineural hearing loss; BUN= blood 






Figure 1. Anatomy of inner ear and hair cells 
 
 
(A) Electron micrograph of normal outer (arrowheads) and inner (arrow) cochlear hair 
cells; (B) Electron micrograph of damaged cochlear hair cells.  




Figure 2. Cross-sectional view of the cochlear duct  
 





Figure 3. Conceptual framework of Adverse Outcome Pathway on AG ototoxicity in MDR-TB treatment 
 
Abbreviations: AG= aminoglycoside; AO= adverse outcome; HIV= human immunodeficiency virus; KE= key event; MDR-TB= multidrug-resistant 
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Setting: Among drug-resistant tuberculosis (DR-TB) patients, permanent hearing loss 
from the ototoxic effects of injectable aminoglycosides (AG) is common. Pre-existing 
hearing loss prior to DR-TB treatment may accelerate further AG ototoxicity compared to 
those with normal hearing at baseline. 
Objective: To determine the risk factors associated with pre-existing hearing loss for 
DR-TB patients in South Africa prior to the initiation of treatment for DR-TB. 
Methods: A cross-sectional study across 10 hospitals in the Eastern Cape and KwaZulu-
Natal provinces of South Africa as part of an ongoing cluster-randomized trial. All 
patients older than 13 years with confirmed DR-TB were included. The clinical, 
audiological and laboratory evaluations were conducted before DR-TB treatment 
initiation. 
Results: Of 936 patients, 54% were male, mean age 36.2 (SD=11.04), 75% HIV 
coinfected, and 11% had a prior history of second-line DR-TB treatment. The prevalence 
of pre-existing auditory symptoms was 15.2% (n=142). Of 482 patients (51.5%) tested at 
baseline by audiometry, 60.2% (n=290) had pre-existing audiometric hearing loss. 
Prevalence of pre-existing auditory symptoms was 5.53 times higher (p<.001) and that of 
pre-existing audiometric hearing loss was 1.63 times higher (p<.001) among patients ≥ 50 
years of age than among teenagers. The prevalence of pre-existing auditory symptoms 
was 1.73 times higher (p <.001) and the unadjusted prevalence of pre-existing 
audiometric hearing loss was 1.33 higher (p=.031) among those who had a prior TB 
history with second-line treatment than among those who never had TB. 
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Conclusions: We found a high prevalence of pre-existing hearing loss in this study 
setting in South Africa. Advanced age and prior second-line TB treatment history were 
significantly associated with higher prevalence of pre-existing hearing loss, particularly 
for DR-TB patients. DR-TB providers should adhere to DR-TB treatment guidelines to 




Tuberculosis (TB) is one of the leading causes of infectious disease-related deaths 
worldwide, and is particularly common and lethal in HIV/AIDS-endemic areas such as 
South Africa.1 A growing concern in South Africa is drug-resistant TB (DR-TB)—TB 
that is resistant to first-line anti-TB drugs rifampicin and/or isoniazid.1,2 DR-TB is treated 
with second-line injectable anti-TB drugs (for at least 4 months), including 
aminoglycosides (AGs) (e.g., amikacin and kanamycin) and polypeptides (e.g., 
capreomycin).2,3 Among DR-TB patients, permanent hearing loss may result from long-
term use of AG due to its ototoxic adverse reaction. Although the exact mechanism of 
AG ototoxicity is not fully understood, one of the hypotheses is that AGs generate free 
radicals within the inner ear, which causes apoptotic death of hair cells and ancillary 
sensory cells within the cochlea.4,5 Such irreversible sensorineural damage leads to 
permanent hearing loss, starting from high frequencies with or without tinnitus.4,5 The 
cumulative incidence of AG-induced hearing loss varies between 24% and 69% for DR-
TB-infected individuals in South Africa,6 and hearing loss is the most common cause of 
AG discontinuation, increasing the risk for treatment failure along with further 
transmission of DR-TB in the household and community.3,7 
 Although it is still unclear who are at higher risk for AG ototoxicity, it has been 
studied that pre-existing hearing loss prior to DR-TB treatment is associated with AG 
ototoxicity compared to patients with normal hearing at baseline.5 Pre-existing 
sensorineural hearing loss at DR-TB diagnosis commonly originates from previous 
exposure to ototoxic drugs, noise exposure, advanced age (presbycusis), or idiopathic 
sensorineural hearing loss.8,9 These conditions also result in irreversible hair cell loss that 
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causes the remaining hair cells to be more vulnerable to apoptosis after AG 
administration. For this reason, the South African Department of Health DR-TB 
treatment guidelines recommend that an AG-sparing regimen should be considered for 
those who have pre-existing hearing loss at baseline evaluation.2 However, due to the 
lack of trained audiologists or testing facilities, pre-existing hearing loss is often 
underdiagnosed at baseline.  
While there is plausible evidence that several pre-treatment health conditions may 
be associated with the presence of pre-existing hearing loss prior to AG treatment that 
intensifies further AG-induced hearing loss, no evidence exists at the population level. 
Aging leads to auditory sensory cell degeneration due to excessive oxidative stress, 
which in turn damages hair cells before, during, and even after AG treatment.10 HIV 
coinfection impacts hearing loss because the virus directly demyelinates the central 
nervous system (CNS) and peripheral auditory nerves or causes opportunistic infections, 
such as cytomegalovirus (CMV) infection that involves CNS or vestibulocochlear 
nerves.11-13 Frequent use of ototoxic drugs to treat opportunistic infection and to manage 
the associated symptoms may increase the risk of AG ototoxicity. Malnutrition may also 
damage the hair cells in the inner ear. Acute malnutrition causes risk of infection of the 
auditory system, and thus untreated or recurring infection leads to hearing loss.14 Chronic 
malnutrition in childhood and young adulthood results in stunted auditory nerve systems, 
causing sensorineural hearing loss.14 In South Africa, a history of DR-TB treatment may 
indicate previous AG exposure.2 As a result, those with a history of DR-TB treatment 
may experience more substantial hearing loss from repeated AG treatment than those 
who never had DR-TB.15-18  
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Since pre-existing hearing loss is directly and indirectly associated with the risk of 
further AG-induced hair cell damage, it is critical to investigate whether pre-existing 
hearing loss has been well screened and how many patients received ototoxic agents in 
spite of pre-existing hearing loss at DR-TB initiation. In addition, there is a need to 
identify the association between pre-existing hearing loss and other risk factors for 
developing hair cell damage in DR-TB-infected populations. Thus, the purpose of this 
study was to determine the prevalence of pre-existing hearing loss and AG ototoxicity 
risk factors prior to the initiation of treatment for DR-TB in South Africa where high 
burdens of TB, HIV, and malnutrition coexist. 
 
METHODS 
Study Design and Setting 
This was a nested cross-sectional study using baseline data collected on treatment 
initiation as part of an ongoing cluster-randomized trial investigating the effects of nurse 
case management in improving treatment outcomes in individuals with DR-TB 
coinfection in the Eastern Cape and KwaZulu-Natal provinces of South Africa. Data were 
collected at 10 public TB hospitals in the Eastern Cape and KwaZulu-Natal provinces. 
The trial has been registered at clinical trials.gov where full details regarding the parent 
study have been reported (NCT02129244).19,20 
 
Participants 
For this sub-study, we included participants enrolled in the parent study from 
November 2014 to June 2017. The following participants were included: older than 13 
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years, with microbiologically confirmed rifampicin-resistant TB, who were tested by 
GeneXpert and eligible for an AG regimen, and signed informed consent within seven 
days of treatment initiation. If participants had been confirmed with drug-sensitive or 
extensively drug-resistant TB from drug sensitivity tests during the 6-month intensive 
phase, they were excluded from the study. Participants were also excluded if they had 
started DR-TB treatment at a different facility or were enrolled in a clinical trial changing 
the standard DR-TB or HIV regimen.  
 
Assessment & Measures 
Pre-existing hearing loss was defined as follows: (1) pre-existing audiometric 
hearing loss: a hearing threshold outside of the normal range (above 25dB) in one or both 
ears at any frequencies in the range from 250 to 8,000 Hz, tested by either a standard 
audio booth or by a computer-based portable audiometer at baseline audiometry 
(KUDUwave®); or (2) pre-existing auditory symptoms: self-reported symptoms of 
hearing loss or tinnitus prior to DR-TB treatment initiation. Auditory symptoms were 
assessed through face-to-face interviews by either nurse case managers (NCMs) or 
research assistants (RAs) of the parent study with the language the patient preferred. 
Participants were asked the following questions at the initial screening visit: “In the last 
month (30 days), before your treatment began, have you had ringing in the ears?” and “In 
the last month (30 days) before your treatment began have you had hearing loss?” The 
responses were collected as five-ordinal variables based on severity of symptoms—from 
no symptom (grade 0) to severely severe (grade 4)—and then it was dichotomized into 
whether auditory symptoms were present or not.  
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Potential risk factors of ototoxicity from clinical and laboratory evaluations—
nutritional status, HIV status, CD4 count, renal function, and audiometry—were 
measured before DR-TB treatment initiation. Particularly, clinical parameters of 
nutritional status included body mass index (BMI) calculated by weight and height, and 
serologic nutritional status of serum albumin. These baseline data were extracted by 
medical chart review and the National Health Laboratory System (NHLS) online 
laboratory portal. Medical history and sociodemographic data, including age, sex, and 
prior TB history, were collected by baseline interviews on the day of the DR-TB 
treatment program admission by NCMs or RAs of the parent study.  
 
Statistical Analysis  
We initially conducted descriptive statistics to present distributions of data using 
frequencies and proportions for categorical variables and mean, and standard deviation 
(SD) or median and interquartile range (IQR) as appropriate for continuous variables. We 
performed bivariate analyses using Pearson’s chi-square test for categorical variables and 
the Wilcoxon rank-sum tests for continuous variables to compare the presence of 
potential risk factors by comparing between-study participants, those who had pre-
existing hearing loss, and those not at baseline. A Poisson regression model with robust 
variance was used to adjust for potential confounding variables and to account for 
clustering of TB hospitals. The model compared the prevalence of risk factors by baseline 
hearing status and presented the prevalence ratio. All statistical analyses were performed 
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Of the 1,279 participants enrolled in the parent study, 936 were eligible for the 
present study to be assessed for pre-existing hearing loss (Figure 1). Mean age was 36.15 
(SD=11.04) and median was 33.99 (IQR=28.11-41.08); 54% were male; 75% were 
coinfected with HIV (n=697). While the majority (63.0%) had a normal renal function 
(eGFR > 90 ml/min/1.73m2), 7.1% had renal impairment (eGFR < 60 ml/min/1.73m2); 
35.2% (n=329) were underweight (BMI < 18.5 kg/m2); 58.9% (n=551) had 
hypoalbuminemia (serum albumin < 35 g/L) and of those, 19.1% had severe 
hypoalbuminemia (serum albumin < 25 g/L). Half of the sample (n=421) had a prior 
history of TB infection in the form of either drug-sensitive or resistant (50.0%), and of 
those, 11.4% had prior DR-TB history treated with second-line anti-TB treatment.   
Of the 697 participants with HIV coinfection, 602 had available baseline CD4 
count data. Median baseline CD4 count was 188 cells/mm3 (IQR= 76-340). More than 
half of HIV-infected patients (53.2%) had a baseline CD4 count below 200 cells/mm3 and 
 
77 
18.1% were extremely immunocompromised (CD4 count < 50 cells/mm3). See Table 1 
for additional participant characteristics.   
 
Prevalence of pre-existing hearing loss  
Of 936 participants, 15.2% reported baseline auditory symptoms (n=142), 
specifically having hearing loss only (n=48), tinnitus only (n= 48), and both (n=46). 
Audiometric outcomes were available at baseline for only 51.5% of participants (n=482). 
More than half (60.2%) of them (n=290) had audiometry-confirmed hearing loss of any 
level at frequencies from 250 to 8,000Hz. About half (50.6%) were tested by computer-
based portable audiometry; the remaining half were tested by standard audio-booth 
audiometry. There was a strong association between the presence of baseline auditory 
symptoms and audiometry-confirmed hearing loss in this study population (χ2(1)=12.98, 
p< .001).  
 
Comparison by pre-existing hearing loss status 
In the bivariate analysis, the following variables had significantly higher 
prevalence among those with pre-existing auditory symptoms than among those without: 
older than 50 years of age (PrR=3.53, p<.001) and prior TB history with second-line 
treatment (PrR= 1.95, p<.001). In the multivariable Poisson regression model, the 
prevalence of pre-existing auditory symptoms among those in their 20s was 2.89 times 
higher (p=.006); for those in their 30s, the prevalence was 5.10 times higher (p<.001); for 
those in their 40s, the prevalence was 3.33 times higher (p<.001); and for those in their 
50s or older, the prevalence was 5.53 times higher (p<.001) than for teenagers after 
 
78 
adjusting for sex, prior TB history, albumin, BMI, and HIV status with CD4 count. In the 
same model, the prevalence of pre-existing auditory symptoms was 1.73 times higher 
among those who had prior TB history with second-line treatment than among those who 
never had TB (p <.001); overweight or obese patients had 32% lower prevalence of pre-
existing auditory symptoms than underweight patients (p <.001) (Table 2).  
In the sub-group analysis of those who had baseline audiometric data, the 
bivariate analysis showed that an age older than 50 was associated with 46% higher 
prevalence of pre-existing audiometric hearing loss than among teenagers (p=.001); 
females had 9% lower prevalence than males (0<.001); those with prior DR-TB with 
second-line treatment history had 33% higher prevalence than new TB patients (p=.031); 
and those who had HIV coinfection with CD4 count less than 200 had 21% higher 
prevalence than those without HIV coinfection (p=.005). In the multivariable model, age 
older than 50 had 1.63 times higher prevalence than teenagers (p<.001), and 1.18 times 
higher prevalence among those with severe hypoalbuminemia (< 25 g/L) than those with 
normal albumin level (p <.001), after adjusting for sex, prior TB history, BMI, and HIV 
status with CD4 count (Table 2).  
 
DISCUSSION 
This study found that the prevalence of pre-existing hearing loss—both auditory 
symptoms and audiometry-confirmed hearing loss—was significantly high among DR-
TB patients in Eastern Cape and Kwazulu-Natal provinces in South Africa. Not 
surprisingly, the higher prevalence of pre-existing hearing loss among patients ≥ 50 years 
of age is cogent evidence that presbycusis is prevalent in this sample even at age 50 or 
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older. This should be accounted for in the selection of DR-TB regimens to prevent 
substantial hearing loss from treatment as both advanced age and pre-existing hearing 
loss aggravate AG-induced hearing loss. A history of previous exposure to second-line 
DR-TB treatment was associated with higher prevalence of pre-existing auditory 
symptoms and with unadjusted prevalence of pre-existing audiometric hearing loss. Such 
findings may be explained by some level of irreversible hair cell damage that had already 
occurred due to previous AG exposure. While none of the models found differences in 
the prevalence of pre-existing hearing loss between BMI categories, the adjusted 
prevalence of pre-existing hearing loss among those with severe hypoalbuminemia was 
18% higher than among those with normal albumin levels. This is an important finding 
because protein-energy malnutrition—as a clinical manifestation of TB infection when 
albumin synthesis is compromised—changes colloid oncotic pressure, resulting in 
abnormal accumulation of fluid in the interstitium of hair cells.22,23 Since excessive AG 
molecular accumulation can occur in the interstitium of hair cells because AG is water-
soluble,24 DR-TB providers should be fully aware that the co-existence of pre-existing 
hearing loss and hypoalbuminemia synergistically enhance the incidence of AG-induced 
hearing loss after the initiation of a DR-TB regimen. In this study population, while the 
prevalence of pre-existing hearing loss and HIV coinfection were not associated, the 
unadjusted prevalence of pre-existing audiometry-confirmed hearing loss among HIV-
coinfected patients with immunosuppression (CD4 count < 200) was 21% higher than 
among HIV-uninfected DR-TB patients. HIV infection not only weakens the host 
immune system—increasing the chance of opportunistic infections and additional use of 
ototoxic agents—but also causes excessive oxidative stress in cellular levels that 
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accelerates oxidative hair cell damage.25 Thus, further development of AG-induced 
hearing loss should be closely monitored during AG treatment for those who are HIV 
coinfected.  
We also found that the evaluation of adherence to practical recommendations for 
baseline hearing screening needs more attention in this study setting. The South African 
Department of Health MDR-TB guidelines instruct that audiometry should be performed 
prior to initiation of treatment and repeated at least monthly throughout the injectable 
phase of treatment.2 However, we found that baseline audiological evaluation was 
inconsistently performed, and only 51.5% in this sample were screened for their baseline 
hearing capacity through audiometry. Moreover, the availability of trained audiologists 
and well-functioning audiometers at TB hospitals should be audited on a regular basis to 
make early detection of AG-induced hearing loss possible in practical settings. 
This study has several limitations. As this is a nested study using secondary data, 
the selection of variables was limited based on the parent study collected data. Since the 
parent study was not designed to primarily inquire about hearing loss from DR-TB 
treatment, other risks of hearing loss, such as noise exposure, conductive hearing loss, 
and family history of hearing loss or ototoxicity, were not collected. Since AG is water-
soluble and the molecular concentration is influenced by body size,26 future studies must 
consider including not only the aforementioned risk factors but also a wider range of 
measures of nutritional status including: (1) body size measured by anthropometric 
parameters (e.g., arm/waist/hip/calf circumferences and triceps/subscapular skinfold), and 
(2) body composition measured by bioelectrical impedance (e.g., fat mass, fat-free mass, 
muscle mass, fat area, muscle area, total body water, intracellular water, and extracellular 
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water). In addition, a comprehensive measure of HIV-related variables, such as duration 
of living with HIV infection, the specific ART combination given and its frequency, 
needs to be considered in future studies. Since height, weight, and audiometry were 
measured by TB hospital staff who had not been trained by the parent study, 
measurement errors might have occurred equally across all sites. These programmatic 
measurements were used by healthcare providers to make clinical decisions including TB 
medication dosing, so they are clinically relevant. Finally, as a cross-sectional study, our 
findings of the associations between pre-existing hearing loss and other ototoxicity risk 
factors can be suggestive of possible risk factors of AG-induced hearing loss, but they 
cannot reflect causal relationships. Thus, further longitudinal studies exploring the 
incidence of AG-induced hearing loss according to the presence of risk factors should be 
conducted to fill such gaps.  
 
CONCLUSION 
This study found a high prevalence of pre-existing hearing loss in DR-TB and 
HIV-endemic settings in South Africa. Advanced age and prior TB history with use of 
second-line anti-TB drugs were significantly associated with a higher prevalence of pre-
existing hearing loss. DR-TB providers should not only adhere to DR-TB treatment 
guidelines to screen those at higher risk for developing AG-induced hearing loss but also 
consider the use of less ototoxic DR-TB regimens for those with advanced age and a 
prior TB treatment history who display pre-existing hearing loss at baseline.   
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Smoking: N (%) 
Non-smoker  
Light smoker (<10 cigarettes/day) 










Alcohol use: N (%) 
Non-drinker 
Less than once per week 






















HIV status & CD4 count†: N (%) 
HIV negative 
HIV positive with CD4 ≥ 200 
HIV positive with CD4 < 200 












Prior history of TB: N (%) 
New TB 
Prior TB with 1st line treatment  













BMI‡: N (%) 
Underweight (<18.5) 
Normal (18.5-24.9) 













Serum Albumin§: N (%) 
Normal (≥ 35) 
Mild hypoalbuminemia (25-34.9) 































*Age unit=years old; †CD4 count unit=cells/mm3; ‡BMI unit=kg/m2; §serum albumin unit= g/L; ‖eGFR 
unit=mL/min/1.73m2 
Abbreviations: ART=Anti-retroviral therapy; BMI=body mass index; CD4=cluster of differentiation 4; 




Table 2. Comparison of the Prevalence Ratios of Ototoxicity Risk Factors by Pre-existing Hearing Loss among Patients with DR-TB  
 Pre-existing auditory symptoms (N=936)  Pre-existing audiometric hearing loss (N=482) 
Variable Unadjusted PrR (95% CI) Adjusted PrP (95% CI)  Unadjusted PrR (95% CI) Adjusted PrR (95% CI) 































Sex 0.99 (0.80-1.23) 0.99 (0.73-1.33)  0.91 (0.88-0.93) 1.00 (0.95-1.06) 
Prior history of TB  
New TB 
Prior TB with 1st line treatment  


















Serum albumin (g/L) 
Normal albumin 
Hypoalbuminemia (< 35) 







































HIV status & CD4 count (cells/mm3) 
HIV negative 
HIV positive with CD4 ≥ 200 


















Type of audiometer 
Audio booth 
KUDUwave 







*Abbreviations: BMI=body mass index; CD4=cluster of differentiation 4; HIV=human immunodeficiency virus; PrR=prevalence ratio; TB=tuberculosis  
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Abbreviations: KM= kanamycin; AMK= amikacin; DS-TB= drug-sensitive tuberculosis; XDR= extensively drug-resistant TB  
 
Assessed for eligibility 
n=1279 Excluded (n=343) 
• DS-TB (n=47) 
• (pre)XDR (n=176) 
• withdrawal at baseline (n=14) 
• Not on KM or AMK (n=106) 
Subjects without baseline audiograms 
n=454 (48.61%) 
Included in study 
 n= 936 
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Setting: A high proportion of individuals with multi-drug-resistant tuberculosis (MDR-
TB) develop permanent hearing loss due to ototoxicity caused by injectable 
aminoglycosides (AGs). The prevalence of AG-induced hearing loss is greatest in 
tuberculosis (TB) and human immunodeficiency virus (HIV) endemic countries in sub-
Saharan Africa. However, whether HIV coinfection is associated with a higher incidence 
of AG-induced hearing loss during MDR-TB treatment is controversial. 
Objective: To evaluate the impact of HIV coinfection on AG-induced hearing loss 
among individuals with MDR-TB in sub-Saharan Africa. 
Design: This was a meta-analysis of articles published in PubMed, Embase, Scopus, 
Cumulative Index to Nursing and Allied Health Literature, Web of Science, Cochrane 
Review, and reference lists using search the terms ‘hearing loss’, ‘aminoglycoside’, and 
‘sub-Saharan Africa’. 
Results: Eight studies conducted in South Africa, Botswana, and Namibia and published 
between 2012 and 2016 were included. As the included studies were homogeneous 
(χ2=8.84, d.f.=7), a fixed-effects model was used. Individuals with MDR-TB and HIV 
coinfection had a 22% higher risk of developing AG-induced hearing loss than non-HIV-
infected individuals (pooled relative risk=1.22; 95% CI=1.10-1.36) during MDR-TB 
treatment.  
Conclusion: This finding is critical for TB programs with regard to the expansion of 
injectable-sparing regimens. Our findings lend credibility to using injectable-sparing 
regimens and more frequent hearing monitoring, particularly in resource-limited settings 




Multidrug-resistant Tuberculosis (MDR-TB), defined as TB resistant to at least 
isoniazid and rifampicin, is a global health emergency. MDR-TB treatment is prolonged 
(9–24 months), poorly efficacious (<50% treatment success), poorly tolerated, and quite 
toxic.1,2 Despite advances in injectable-sparing regimens, the mainstay of MDR-TB 
treatment contains one second-line injectable, an aminoglycoside (AG), for at least 4 
months in combination with four oral drugs.2 AGs include amikacin (AMK), kanamycin 
(KM), and streptomycin (SM), or the mechanistically similar cyclic peptide antibiotic, 
capreomycin (CPM).3 One of the main adverse reactions from AGs is sensorineural 
ototoxicity: SM is mainly vestibulotoxic, causing dizziness, ataxia, or nystagmus; AMK, 
KM, and CPM are predominantly cochleotoxic, resulting in tinnitus or hearing loss.4 
AG-induced hearing loss begins at high frequencies, can progress even with AG 
discontinuation, and is permanent unless quickly identified.4 Hearing loss leads to social 
isolation, reduced quality of life, and threatens employment stability and family 
prosperity.5,6 The risk of AG-induced hearing loss may be impacted by human 
immunodeficiency virus (HIV) coinfection. Although the exact mechanism of AG 
ototoxicity is not known, it has been hypothesized that excessive AG accumulation in the 
inner ear catalyzes the formation of reactive oxygen species (ROS).7,8 When ROS 
formation overwhelms the capacity of the intrinsic protective and repair system, the 
sensory hair cells undergo apoptotic death, resulting in irreversible hearing loss.4,9 As 
chronic immune activation in HIV coinfection triggers massive ROS formation, people 
living with HIV (PLHIV)—particularly those who are antiretroviral therapy (ART) 
naïve—may be more vulnerable to AG ototoxicity.10,11 
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Paradoxically, HIV treatment may also be associated with an increased risk of 
ototoxicity. Nucleoside reverse transcriptase inhibitors (NRTIs), a class of ART drugs, 
are mitochondrial-toxic and cause mitochondrial damage in outer hair cells.12,13 
Moreover, one NRTI, tenofovir disoproxil fumarate, is also nephrotoxic, and can 
compound AG-induced ototoxicity, as AGs are eliminated through the kidneys.12,13 Poly-
pharmacy is common in MDR-TB and HIV treatment, with additional medications added 
to manage opportunistic infections or adverse drug reactions.14 This complexity may 
result in additional drug-drug interactions, pill fatigue and resultant non-adherence, or 
drug-induced renal impairment, any of which can affect the risk of ototoxicity.15 
People in resource-limited settings are more likely to be at high risk for AG 
ototoxicity. Protein-energy malnutrition caused by insufficient intake of protein and 
calories is prominent in sub-Saharan Africa due to food insecurity.16,17 In the case of 
protein-energy malnutrition, albumin synthesis is impaired and changes in oncotic 
pressure lead to abnormal accumulation of fluid in the interstitium of hair cells,18,19 
thereby worsening AG ototoxicity because AG is water-soluble.20 Furthermore, a dietary 
deficiency of protein and calories reduces the synthesis of antioxidant enzymes and 
antioxidant concentrations, leading to ROS overproduction.19,21 Due to the financial costs 
involved in frequent audiological assessment or therapeutic drug monitoring (i.e., daily 
blood tests for AG concentration), early detection of hearing loss is impractical in most 
sub-Saharan African countries, which leads to missed opportunities to prevent hearing 
loss.1,22 
Despite these known risks, whether HIV coinfection leads to a higher incidence of 
AG-induced hearing loss during MDR-TB treatment is controversial. The objective of the 
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present study was to systematically review the literature and estimate the effect size of 
the association between HIV coinfection and AG-induced hearing loss among MDR-TB-
infected individuals in sub-Saharan Africa. 
 
METHODS 
The review process was guided by the Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) standards.23 Institutional review board approval 
was not required for this meta-analysis. 
 
Inclusion/exclusion Criteria 
The inclusion criteria for participants were: (1) known or presumptive TB with 
isoniazid resistance, rifampicin resistance, or MDR-TB on microbiologic tests 
(determined either on culture with drug susceptibility testing or using cartridge-based 
Xpert® MTB/RIF; Cepheid, Sunnyvale, CA, USA), and (2) use of second-line injectable 
anti-tuberculosis drugs (AMK, KM, SM, or CPM). Hearing loss in study participants 
should have been observed either prospectively or retrospectively during and/or after 
treatment with injectables. All ages and both sexes were included in our analyses. 
The following diagnoses of AG-induced hearing loss were accepted: (1) 
audiometric hearing loss, defined as worsening of hearing threshold confirmed using 
audiometry; (2) self-reported hearing loss, defined as symptomatic hearing loss reported 
by patients after AG initiation; and (3) clinician-identified hearing loss, diagnosed by 
clinicians in the absence of audiometry. In our analysis, a broader definition of AG-
induced hearing loss was accepted because regular audiological assessments are rarely 
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conducted in many sub-Saharan African countries due to the shortage of trained 
audiologists or testing equipment. This definition of hearing loss was supported by a 
recent study that concluded that patient self-report of hearing loss was highly concordant 
with clinician-identified hearing loss in the setting of monthly audiological testing.24 
Only studies written in English were included. 
Studies were excluded if they did not include participants’ HIV status as a study 
variable. We also excluded studies if full-text versions were not available (e.g., 
conference abstracts), if the study did not have a quantitative design, or if studies reported 
the protocol only with no measured outcomes. 
 
Search and Selection Process 
PubMed, Embase, Cumulative Index to Nursing and Allied Health Literature 
(CINAHL), Scopus, Web of Science, and Cochrane Review were searched using the 
following MeSH terms: ‘hearing loss’, ‘aminoglycosides’ and ‘Africa South of the 
Sahara’. Our initial search was not limited by the year of publication. Electronic searches 
were supplemented by manual searches of references found in identified articles and 
bibliographies. 
Our initial database search, conducted on 19 December 2016, resulted in 367 
citations. After removing duplicates, 79 titles with abstracts were reviewed for relevance 
by HH. Twenty-one articles were passed onto the next full-text review process. Of the 12 
full-text articles that were selected by HH and confirmed by CB, six studies reporting the 
number of participants who developed AG-induced hearing loss and their baseline HIV 
coinfection status provided useful data for a meta-analysis. We contacted the six 
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corresponding authors of the eligible studies to request unpublished descriptive statistical 
data to calculate the cumulative incidence of hearing loss and prevalence of HIV 
coinfection; of these, two authors provided the requested data, which were finally added 
to the study data set on 10 July 2017. Eight studies were included in our analysis; four 
studies were excluded due to lack of useful data required for a meta-analysis (Appendix 
Figure A.1). 
 
Data Quality Assessment  
The Newcastle-Ottawa Quality Assessment Scale (NOS) was used to evaluate the 
quality of the original studies.25 Three main themes were evaluated: selection of samples 
(four items), comparability of cohorts (one item), and ascertainment of outcome (three 
items). 
In this meta-analysis, comparability was assessed as to whether the original 
studies isolated conductive hearing loss (e.g., cerumen impaction or middle ear infection) 
using otoscopy or tympanometry, because AG mainly causes cochlear-toxic sensorineural 
hearing loss. One point was awarded for each quality item; a total of eight points thus 
indicated the highest quality. In general, as positive findings are more likely to be 
published, we also tested for publication bias to estimate the possibility of distortion of 
synthesized meta-analysis results.26 
 
Statistical Analysis 
Cumulative incidence (absolute risk, i.e., the total number of events divided by 
the total number of people at risk) of each study was initially calculated because of the 
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different follow-up durations and formats used to measure events across studies.27 
Heterogeneity was tested using Cochran’s Q statistic, along with summary estimates 
using the metan command. Due to non-significance of heterogeneity (χ2 =8.84, d.f.=7, 
p=0.26; I2= 20.9%), which suggested that the differences between the studies were 
explicable by random variation,28 we used the Mantel-Haenszel fixed-effects method 
with the metan command in Stata/IC 14 (StataCorp, College Station, TX, USA) to 
combine the different results and obtain a pooled estimate of the effect size.28,29 The 
cumulative incidence ratio (relative risk [RR]) was used as a pooled measure of 
association to interpret the synthesized impact of the prevalence of HIV coinfection on 
the risk of AG-induced hearing loss, with variance presented by 95% confidence intervals 
(CIs). The funnel plot—a graphic plot to diagnose publication bias and other small-study 
effects (the tendency for smaller studies in a meta-analysis to show larger treatment 
effects)—was used using the funnel command.28,29 
 
RESULTS 
Overview of studies included in the meta-analysis 
This meta-analysis comprised eight studies that met the inclusion and exclusion 
criteria (Table). All eight studies were published between 2012 and 2016.13,24,30–35 Most 
were prospective and retrospective cohort studies; one study retrospectively collected 
study outcomes from medical records and then compared these to cross-sectional patient 
interview outcomes.24 The studies were conducted in specialist TB hospitals 
(n=7)13,24,30,32–35 and community-based HIV-TB clinical settings (n=1).31 Seven studies 
had a cohort sample of adults aged ≥14 years;13,24,31–35 only one study had a sample of 
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children aged <15 years.30 Sample size was between 50 and 99 individuals in four 
studies,30–32,34 between 100 and 299 in two studies,13,24 and >300 in two studies.33,35 All 
studies were conducted in southern Africa: four studies were conducted in South 
Africa,13,24,30,31 two in Botswana33,34 and two in Namibia.32,35 NOS scores ranged between 
5 and 8; the mean was 6.75 out of 8. 
The outcomes of hearing loss diagnosis were categorized by audiometric hearing 
loss (n=3)13,30,35 and composite hearing loss, including both clinician-identified hearing 
loss confirmed using audiometry (n=4)24,31,33,34 and self-reported hearing loss (n=1).32 
Audiometric hearing loss was assessed using either pure tone audiometry in adults and 
children aged >7 years or distortion product otoacoustic emissions in children aged <6 
years.30 Of the five studies that used audiometry testing of both air and bone conductions 
to diagnose drug-induced sensorineural hearing loss, only two studies confirmed and 
differentiated conductive hearing loss by assessing outer and middle ears through 
tympanometry or otoscopy.13,30 Finally, the risk of hearing loss during injectable anti-
tuberculosis treatment ranged from 23% to 69%. The prevalence of HIV coinfection at 
TB treatment initiation ranged from 30% to 83%. 
 
Effect of human immunodeficiency virus coinfection on aminoglycoside-induced 
hearing loss 
MDR-TB and HIV-coinfected individuals had a 22% higher risk of developing 
AG-induced hearing loss than non-HIV-infected individuals (pooled RR=1.22, 95% 
CI=1.10-1.36, p<.001) during MDR-TB treatment (Figure 1).13,24,30–35 No significant 
differences were found in subgroup analysis of studies for which audiometric hearing loss 
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data were available (n=5). Such analyses demonstrated that the risk of hearing loss was 
24% higher among HIV-coinfected individuals than among non-HIV-infected individuals 
(pooled RR=1.24, 95% CI=1.11-1.38, p<.001) (Figure 2). As shown in Figure 3, three 
studies compared the effect of participants’ ART status on AG-induced hearing loss, 
although the type of ART was not specified; the risk of developing AG-induced hearing 
loss did not differ, regardless of ART status in PLHIV (pooled RR=1.01, 95% CI=0.72-
1.41, p=0.97).24,31,33 Baseline CD4 count was available from only one study, and patients 
whose baseline CD4 count was <200 cells/mm3 did not have a significantly increased risk 
of hearing loss compared to those with a baseline CD4 count ≥200 cells/mm3 (RR=1.16, 
95% CI=0.95-1.42, p=0.15).33 
 
Publication bias 
The asymmetric distribution funnel plots suggested some visual evidence of 
publication bias (Appendix Figure A.2); however, the effect size of AG-induced hearing 
loss was considered to be small. The homogeneity from Q statistics and significant P 
values for effect size supported the characteristics of stability, suggesting reasonably low 
levels of publication bias. 
 
DISCUSSION 
Questions are frequently raised about the risk of treatment-induced hearing loss. 
However, few studies have focused on the factors that might result in a higher risk of AG 
ototoxicity during MDR-TB treatment in sub-Saharan Africa. Although mitochondrial 
mutations in MT-RNR1 may increase genetic susceptibility,36,37 this is more prevalent in 
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Europeans and Asians and not in sub-Saharan Black Africans, among whom the 
prevalence of this mutation is extremely low (0–0.09%).37–40 
We found that individuals with MDR-TB and HIV coinfection had a higher risk 
of AG-induced hearing loss than non-HIV-infected MDR-TB patients. It is therefore 
likely that the high burden of HIV coinfection in sub-Saharan Africa may be the reason 
for the staggeringly high prevalence of AG-induced hearing loss (23–69%) compared 
with less burdened countries, such as the United States (13%),41 the Netherlands (18%),42 
the United Kingdom (28%),43 and India (10–25%).44–46 
We also revealed that AMK was the most common choice of AG for MDR-TB 
treatment across all eight studies. However, one of the included studies found that the risk 
of ototoxicity with AMK was four times higher than with KM (adjusted odds ratio 4.0, 
95%CI 1.5–10.8).35 These findings will assist healthcare providers develop personalized 
interventions, for example by choosing less ototoxic drugs, changing to an AG-sparing 
regimen, or scheduling more frequent hearing monitoring in PLHIV where AG is 
required for MDR-TB treatment, especially in sub-Saharan Africa.  
A new short-course MDR-TB treatment regimen recommended by the World 
Health Organization (WHO) reduces treatment from 20–24 months to 9–12 months; 
however, an injectable AG remains part of this recommendation, in part because of the 
low cost as well as potent antibacterial activities.2,4 To qualify for substitution of less or 
non-ototoxic drugs (e.g., bedaquiline) for AGs, many TB programs currently require 
evidence of treatment-related hearing loss. All patients’ hearing should therefore be 
carefully monitored while using second-line injectable AGs through routine audiological 
assessments for the early detection of hearing loss. Regular audiological assessments may 
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prevent severe or complete hearing loss because, by the time a symptom of hearing loss is 
detected, it is often too late to reverse hair cell damage.4 
In our meta-analysis, only three studies used an audiometric definition of hearing 
loss for all study participants,13,24,35 while others embraced self-reported or clinician-
identified hearing loss as a surrogate outcome of hearing loss. Our meta-analysis also 
found that only two of eight studies conducted tympanometry and otoscopy to confirm 
drug-induced sensorineural hearing loss by differentiating it from conductive hearing 
loss.13,30 These findings suggest that regular and comprehensive audiological assessment 
may be impractical in many study sites due to insufficient resources. 
The present study has several strengths. First, we used PRISMA criteria to 
increase the transparency of reporting and avoid selection bias during the study selection 
phase.23 Second, we conducted a comprehensive search of all potentially relevant studies 
with the help of an academic librarian to ensure a systematic approach to capture all the 
evidence that may pertain to the question of interest. Third, the NOS tool was used to 
assess the quality of all included studies so that results could be interpreted in the context 
of their quality. Finally, we used a meta-analysis, a rigorous statistical method, to 
consolidate research findings from studies addressing a similar topic but conducted in 
diverse settings.47,48 This approach enabled the analysis to draw more decisive 
conclusions on effect size for a relationship between AG-induced hearing loss and HIV 
coinfection because of its greater statistical power and external validity.47 
While our study findings contributed to the risk analyses of AG-induced hearing 
loss, there were several limitations. First, despite our expanded search criteria, only a 
small number of studies met the inclusion criteria due to the lack of published studies. As 
 
101 
very few studies reported the ART status of participants, we were unable to conclude 
whether concomitant administration of ART affected the risk of AG-induced hearing loss 
during injectable MDR-TB treatment. Second, samples of included studies were not 
necessarily representative of the variety of people living in sub-Saharan Africa, as the 
geographical sites of the included studies were mostly limited to southern Africa, and 
participants were predominantly adults. Finally, this meta-analysis did not control for 
potential confounders, such as age or use of ototoxic or nephrotoxic drugs, during 
injectable treatment. 
Future studies aiming to find AG-induced hearing loss risk factors or prevent AG-
induced hearing loss must consider including a wide range of HIV-related variables, such 
as CD4 count, viral load, duration of living with HIV infection, as well as the specific 
ART combination given and its frequency. Future studies need to consider the influences 
of time-dependent variables, such as weight, serum creatinine, and AG accumulation on 
the risk of AG-induced hearing loss. Because conductive hearing loss commonly results 
from otitis media or cerumen impaction that can threaten construct validity, conductive 
hearing loss must be ruled out by comprehensive audiological assessment, including 
audiometry, tympanometry, and otoscopy.49 Finally, children need to receive more 
attention in AG-induced hearing loss studies, as children with hearing loss may suffer 
from delayed communicational development and literacy compared with children with 





The WHO recommends a new short-course MDR-TB treatment regimen, which 
includes an AG. The present study lends credibility to using injectable-sparing regimens 
and more frequent hearing monitoring—particularly in resource-limited settings for 
PLHIV in sub-Saharan Africa. Such strong evidence of AG-induced hearing loss risk 
may help healthcare providers make clinical decisions when initiating MDR-TB 
treatment for PLHIV. 
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AGs (%) Major Findings 
Harris et al.13 
2012 
(South Africa) 
Prospective cohort (8) 
N= 153  
Adults 
[range=14-70y] 
To document the 
incidence of ototoxicity 
in MDR-TB patients 
with and without HIV, 
and develop clinical 
guidelines relating to 
ototoxicity in such 
patients 














• 57% developed 
high-frequency HL 
within 3m.  
• Of those who 
developed HL, 69% 
were HIV positive 
and 31% were HIV 
negative.  
Seddon et al.30 
2012 
(South Africa) 
Prospective cohort (8) 
N=93 (Confirmed 
MDR-TB n= 50) 
Children  
[IQR=20-110m] 
To determine the extent 
of hearing loss in children 
treated for MDR-TB 
• Audiometric HL by 
PTA  
• Audiometric HL by 
DPOAE  











• 64% had 
audiometric HL 
and had 
progression of HL 
after finishing the 
injectable drug. 







[IQR= 29-41y]  
To examine the frequency 
and severity of AEs in 
patients with MDR-TB 
and HIV coinfection 
treated at an integrated 
MDR-TB/HIV home-
based treatment program  










KM (100) • 34% developed HL 
during treatment.  
• 69% had some 
degree of HL; 11% 




kanamycin for HL.  











No age restriction 
[range= 11-55y] 
To compare the absolute 
risks and risk factors for 
commonly observed 
adverse events (occurring 
in >20 % of patients) 
during DR-TB treatment 










• 23 % developed HL 
during treatment.  
• The absolute risk of 
HL was 8/31 
(26 %) in HIV-
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in HIV-infected and HIV-
uninfected patients. 
coinfected and 5/26 










[IQR= 31-49y]  
To determine the effect of 
amikacin on treatment 
outcomes and 
development of hearing 
loss in MDR-TB patients 










AMK(100) • HIV infection was 
not associated with 
increased risk of 
HL (aOR= 1.32, 
95% CI: 0.83-2.12).  
• The most important 
HL risk factors 
were treatment 
duration in month 




1.15, 95% CI 1.04-
1.28).  

















To identify clinical 
factors, including 
amikacin concentration 
thresholds that predicted 
audiometry-confirmed 
ototoxicity among MDR 
pulmonary TB patients 










AMK(100) • A 10% probability 
of ototoxicity 
occurred with a 
threshold 
cumulative AUC of 
87,232 
days·mg·h/liter, 
while that of 20% 
occurred at 120,000 
days·mg·h/liter. 










No age restriction  
To compare the 
cumulative incidence of 
hearing loss among 
patients treated for MDR-
TB with amikacin or 
kanamycin-based 










• Patients received 
Am had a higher 
risk of developing 
more severe HL 
than those used Km 
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[mean (SD)= 35.69y 
(9.56) in Am; 36.47y 
(11.57) in Km group] 
regimens, and to identify 
the most-at-risk patients, 
based on the real-life 
clinical practice 
experiences 
(aOR= 4.0, 95% CI 
1.5-10.8).  
• HIV coinfection 
(OR= 3.4, 95% CI 
1.1-10.6), male sex 
(OR= 4.5, 95% CI 
1.5-13.4) and lower 
baseline body 
weight (40-59 kg, 
OR= 2.8, 95% CI 
1.1-6.8) were 
associated with 
increased risk of 
HL. 
Kelly et al.24 
2016 
(South Africa) 





To describe concordance 
between patient report 
and clinician 
documentation of ADR 
from MDR-TB treatment 






N/S • Among ADRs from 
MDR-TB 
treatment, the 





HL (kappa= 0.23). 




Abbreviations: NOS=Newcastle-Ottawa Quality Assessment Scale; HIV=human immunodeficiency virus; ART=antiretroviral therapy; AG=aminoglycoside; 
MDR-TB=multidrug-resistant tuberculosis; PTA=pure tone audiometry; AMK=amikacin; KM=kanamycin; SM=streptomycin; CPM=capreomycin; 
IQR=interquartile range; DPOAE=distortion product otoacoustic emissions; AE=adverse effect; DR-TB=drug-resistant tuberculosis; aOR=adjusted OR; 




Figure 1. Effect of HIV Coinfection on Risk of AG-Induced Hearing Loss  
Author Year Country N AG Type RR 95% CI Weight 
(%) 
Forest Plot 
Harris et al.13 2012 South Africa 151 AMK, KM, SM, CPM 1.73 1.25 2.39 11.01 
 
Seddon et al.30 2012 South Africa 93 AMK, SM, CPM 1.50 0.84 2.68 3.05 
Brust et al.31 2013 South Africa 91 KM 0.83 0.42 1.67 3.63 
Sagwa et al.32 2013 Namibia 57 AMK, KM, SM, CPM 1.34 0.50 3.61 1.97 
Modongo et al.33 2014 Botswana 437 AMK 1.13 0.96 1.33 40.64 
Modongo et al.34 2015 Botswana 28 AMK 0.76 0.29 2.02 2.18 
Sagwa et al.35 2015 Namibia 342 AMK, KM 1.18 0.99 1.40 33.75 
Kelly et al.24 2016 South Africa 121 N/S 1.58 0.78 3.20 3.78 
Mantel-Haenszel pooled RR 1.22 1.10 1.36 100.00 
Abbreviations: HIV=human immunodeficiency virus; N=sample size; AG=aminoglycoside; RR=relative risk; CI=confidence interval; AMK=amikacin; 





Figure 2. Effect of HIV Coinfection on Risk of AG-Induced Hearing Loss Confirmed by Audiometry 
Author Year Country N AG Type RR 95% CI Weight 
(%) 
Forest Plot 
Harris et al.13 2012 South Africa 151 AMK, KM, SM, CPM 1.68 1.22 2.31 13.49 
 
Seddon et al.30 2012 South Africa 93 AMK, SM, CPM 1.94 0.64 5.82 1.58 
Modongo et al.33 2014 Botswana 437 AMK 1.16 0.99 1.36 42.30 
Modongo et al.34 2015 Botswana 28 AMK 0.56 0.14 2.33 1.83 
Sagwa et al.35 2015 Namibia 342 AMK, KM 1.18 0.99 1.40 40.80 
Mantel-Haenszel pooled RR 1.24 1.11 1.38 100.00 
Abbreviations: HIV=human immunodeficiency; virus; N=sample size; AG=aminoglycoside; RR=relative risk; CI=confidence interval; AMK=amikacin; 
KM=kanamycin; SM=streptomycin; CPM=capreomycin.
1.0 1.24 7.42 
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Figure 3. Effect of ART status on Risk of AG-induced Hearing Loss  
Author Year Country N AG type RR 95% CI Weight 
(%) 
Forest Plot 
Brust et al.31 2013 South Africa 91 KM 0.81 0.40 1.64 26.74 
 
Modongo et al.33 2014 Botswana 286 AMK 1.38 0.85 2.23 45.03 
Kelly et al.24 2016 South Africa 90 N/S 0.60 0.32 1.13 28.23 
Mantel-Haenszel pooled RR 1.01 0.72 1.41 100.00 
Abbreviations: ART=antiretroviral therapy; N=sample size; AG=aminoglycoside; RR=relative risk; CI=confidence interval; KM=kanamycin; AMK=amikacin; 
N/S= Not specified. 
.323 1.01 3.1 
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Records identified through 
database searching: N= 367 
(PubMed = 102; Embase = 176;  
CINAHL = 21; Scopus = 58; 

































 Additional records identified 
through other sources: N= 1 
 
(Manual search = 1) 
Records after duplicates removed  
(n = 79) 
Records screened  
(n = 21) 
Records excluded (n = 58) 
• Inappropriate study designs 
• Non-target populations 
• Conducted outside sub-
Saharan Africa 
 
Full-text articles assessed 
for eligibility (n = 12) 
Studies included in meta-analysis (n = 8) 
Full-text articles excluded  
(n = 4) 
• Ineligible data for analysis 
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Setting: Aminoglycosides (AGs) are a mainstay of multidrug-resistant tuberculosis 
(MDR-TB) treatment; however, the ototoxic effects of AGs that lead to permanent 
hearing loss are a growing concern in MDR-TB treatment. Since AG ototoxicity is dose-
dependent, the impact of a surrogate measure of AG concentration on AG-induced 
hearing loss warrants close attention.  
Objective: To explore the prognostic impact of cumulative AG exposure on AG-induced 
hearing loss in patients following initiation of AG-containing multidrug therapy for 
MDR-TB. 
Design: This prospective cohort study is nested within an ongoing cluster-randomized 
trial of nurse case management intervention across 10 MDR-TB hospitals in South 
Africa. The data for this study were collected from November 2014 to June 2017.  
Results: The adjusted hazard of AG regimen modification that resulted from ototoxicity 
among the high-exposure group (≥75mg/kg/week) was 1.33 times higher than the low-
exposure group (<75 mg/kg/week; p=.006). The adjusted hazard of developing 
audiometric hearing loss was 1.34 times higher than the low-exposure group (p=.038). 
Pre-existing hearing loss (aHR=1.71, p<.001) and age (aHR=1.02, p=.031) were also 
associated with an increased hazard of hearing loss.  
Conclusion: MDR-TB patients with high AG exposure with advanced age and pre-
existing hearing loss have a significantly higher hazard of AG-induced hearing loss. 
Those at high risk need to receive more frequent monitoring of hearing loss or an AG-




Multidrug-resistant tuberculosis (MDR-TB) is mycobacterium TB resistant to 
both first-line anti-TB drugs (isoniazid and rifampicin) and is treated with at least 4-6 
months of injectable aminoglycoside (AG), such as kanamycin or amikacin.1 During the 
first 4-6 months of treatment, a large proportion of MDR-TB patients develop permanent 
hearing loss due to irreversible apoptotic hair cell damage in the cochlea.2,3 AG-induced 
hearing loss begins with high-frequency hearing loss with or without tinnitus prior to 
presentation of hearing loss in audible lower frequencies.4,5 AG ototoxicity may cause 
early AG regimen modification (i.e., reduced or discontinued), leading to failed or 
delayed TB culture conversion due to attenuated bactericidal efficacy of AG, particularly 
in resource-limited settings without a substitute for AG. 
Despite the known risk of AG-induced hearing loss, selections and availability of less 
ototoxic antibiotics or intensive monitoring of hearing loss are constrained because of 
limited public health resources in South Africa. The following factors worsen a patient’s 
potential risk for AG-induced hearing loss during MDR-TB treatment: excessive AG 
concentration, pre-existing hearing loss, renal impairment, coinfection with HIV, severe 
systemic inflammation, malnutrition, advanced age, and several demographic factors. 
Among these risk factors, cumulative AG exposure needs to receive more attention 
because ototoxicity is dose-dependent.6 Maintaining therapeutic level of AG 
concentration aids in hearing loss prevention and cure of MDR-TB, but frequent blood 
testing for drug concentration is not feasible in South Africa. Thus, we hypothesized that 
patients with high cumulative (or weekly) AG exposure—served as a surrogate measure 
of longitudinal AG concentrations—would have a shorter time to developing hearing loss 
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than those with lower cumulative exposure. The purpose of this study was to explore the 
prognostic impact of cumulative AG exposure on AG-induced hearing loss in patients 
following initiation of AG-containing multidrug therapy for MDR-TB.  
 
METHODS 
Study Design and Setting 
This prospective cohort study was nested within an ongoing cluster randomized 
clinical trial of a nurse case management (NCM) intervention to improve MDR-TB 
treatment outcomes in Eastern Cape and KwaZulu-Natal provinces of South Africa. The 
parent study enrolled participants in 10 public TB hospitals chosen because they followed 
national MDR-TB treatment guidelines and had access to HIV treatment on-site. From a 
pilot study, these hospitals were randomized by location and size to a nurse case 
management intervention.7 Full details regarding the parent study have been reported 
(NCT02129244). Participants in the parent study included individuals 13 years of age and 
older receiving care at the study sites and willing to participate by providing informed 
consent. Participants were excluded from the parent study if they started MDR-TB 
treatment at a different facility or were enrolled in another clinical trial that impacted 
their HIV or MDR-TB treatment regimen.  
 
Standard of Care of DR-TB  
According to the South African National Department of Health guidelines, the 
standard MDR-TB regimen consists of at least 4-6 months of intensive phase treatment 
(aka injectable phase) with one intramuscular injectable AG (e.g., kanamycin or 
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amikacin) and at least four oral antimycobacterials (e.g., moxifloxacin, ethionamide, 
terizidone, and pyrazinamide with or without being further strengthened with high-dose 
isoniazid and/or ethambutol).1,8 The initial AG dose is based on the patients’ baseline 
weight—15mg x weight (kg)—and on the weight band-dosing table guides selection of 
dose (mL) in practice.8 The frequency of AG dosing varied from one to seven times a 
week and is determined by physicians’ clinical judgement, based on patients’ pre-existing 
conditions at the baseline evaluation. The clinical and laboratory evaluations are 
conducted at baseline and every month during the intensive phase.  
 
Prospective Cohort Sample 
For this prospective cohort, we included participants enrolled in the parent study 
from November 2014 to June 2017 and of all ages (13 years and older) because 
adolescents are also at risk for hearing loss from AGs.9-12 We excluded patients with the 
following conditions: (1) those receiving neither intramuscular kanamycin nor amikacin 
injection, (2) participants who were finally confirmed to have drug-sensitive or 
extensively drug-resistant TB from the baseline drug sensitivity tests that resulted during 
the intensive phase, and (3) those who transferred to another TB facility during the 
intensive phase.  
 
Study Procedures and Measures 
The following clinical parameters were abstracted from the parent study: TB 
diagnostic results (i.e., smear, cartridge-based Xpert®, line probe assay, sputum culture, 
and drug sensitivity test), medical history that included previous TB history and HIV 
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status, TB treatment regimen and ART (if applicable), weight, height, audiological 
findings, chest X-ray to confirm cavitary disease, serum creatinine, adverse drug 
reactions, and treatment adherence.8 Data for the parent study were mainly collected by 
NCMs at 5 intervention sites or by research assistants (RAs) at 5 control sites. On the day 
of admission to the MDR-TB treatment program, patients were interviewed for 
sociodemographic data, medical history, and self-reported symptoms. Then other data 
were also collected through medical chart review and the National Health Laboratory 
System (NHLS) online laboratory portal. All sites record weekly data from baseline to 
the end of the intensive phase of MDR-TB treatment, including DR-TB medication 
changes and audiological findings based on chart review and patient interviews. RAs at 
the control sites collected baseline data from the medical records, NHLS online portal, 
and baseline patient interviews.  
Since the parent study was not designed to inquire about hearing loss from DR-
TB treatment, several study variables were additionally collected by the first author. The 
first author collected albumin levels from NHLS because baseline serum albumin results 
were available as part of the routine laboratory test for all MDR-TB patients. Also, 
audiograms were captured by medical chart review to achieve specific audiological data 
at each frequency to define study outcomes of hearing loss. Hearing threshold—the 
lowest intensity of sound in decibels (dB) that the person can hear—was tested at 
baseline, monthly, and whenever the patient’s hearing condition worsens as well by an 
audiometer in a standard audio booth or by KUDUwave® (a computer-based portable 
audiometer)13 at frequencies ranging from 250 to 8,000 Hz.14 Then, the hearing threshold 
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was categorized as degree of hearing loss to define having outcome (See Table 1 for 
detailed description of study variables and degree of hearing loss categories). 
The present study defined pre-existing composite hearing loss as: (1) a hearing 
threshold outside of the normal range between -10 and 25dB in one or both ears at any 
frequency in the range from 250 to 8,000 Hz, tested by baseline audiometry (i.e., pre-
existing audiometric hearing loss); or (2) self-reported auditory symptoms including 
tinnitus or hearing loss. The outcomes of AG-induced hearing loss were further defined 
as: (1) clinically-determined hearing loss resulting in a change in treatment (i.e., reduced 
or stopped AG) due to ototoxicity confirmed by either audiological evaluation or self-
reported symptoms of hearing loss or tinnitus; or (2) audiometric hearing loss defined as 
a deterioration of at least one category of hearing loss compared to baseline hearing in the 
same range of frequencies in one or both ears. The proxy measure of cumulative AG 
exposure following treatment initiation was calculated as: (1) weekly AG exposure = 
prescribed daily AG dose (mg) x frequency of dosing over week (times per week), which 
was categorized into high- (5000+ mg/week), medium- (3000-4999 mg/week) and low-
AG exposure groups (< 3000 mg/week); and (2) standardized weekly AG exposure =  
prescribed daily AG dose (mg) x frequency of dosing over week (times per week)
weight (kg)
 
which was dichotomized by high- (≥75 mg/kg/week) and low-exposure (<75 
mg/kg/week).  
 
Ethical Approval  
The parent study was approved by the Provincial Health Research Committee of 
the Eastern Cape and KwaZulu-Natal Provincial Departments of Health in South Africa. 
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The parent study and this sub-study were both approved by the Biomedical Research and 
Ethics Committee of the University of KwaZulu-Natal in South Africa and the 
Institutional Review Board of the Johns Hopkins Medical Institutions (NA_00078899 / 
CIR00024657).   
 
Statistical Analysis  
Statistical analysis included descriptive and correlational statistics to explore the 
prevalence of hearing loss and risk factors and their associations. Initially, bivariate 
analysis was conducted to examine the impact of cumulative AG exposure on time to 
developing AG-induced hearing loss and estimate effect size. Bivariate analysis was also 
conducted on potential confounders including age, AG type, pre-existing hearing loss, 
CD4 count, eGFR, weight, NCM intervention group assignment, and other demographic 
factors to assess their relationship with AG-induced hearing loss development. Next, 
statistically and clinically significant variables were entered into a multivariable model to 
account for the multicollinearity between confounders and to understand the unique 
contribution of each risk factor to hearing loss. A Cox proportional-hazard model was 
also used to explore hazard ratios for the time to developing AG-induced hearing loss 
adjusting for renal function, age, and pre-existing hearing loss as a primary predictor as 
well as other covariates significant with a p-value <0.05 in bivariate analysis. We 
separated our sample as two cohorts based on audiogram availability and outcome of 
interest. In the clinically-determined hearing loss cohort, using all participants’ data 
regardless of the availability of audiogram, we tested whether weekly AG exposure 
impacted time to AG regimen modification either discontinued or reduced resulted from 
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ototoxicity based on providers’ clinical evaluation. The subset of the audiometric hearing 
loss cohort was used to evaluate whether standardized weekly AG exposure impacted 
time to developing audiometry-confirmed hearing loss. 
 
RESULTS 
Of the 1,279 participants enrolled in the parent study, 936 were eligible for the 
present study and assessed for time to developing clinically-determined hearing loss (See 
Figure 1). Mean age was 36.15 (SD=11.04) years; 54% were male; 75% were coinfected 
with HIV (n= 697); and 62% (n=432) had known exposure to anti-retroviral therapy 
(ART) at baseline. Of the 602 patients with a baseline CD4 count available (median=188 
cells/mm3), over 53% of patients had a CD4 count below 200 cells/mm3 and 18% had a 
CD4 count of 50 cells/mm3 or lower.  
Most of the sample (63%) had a normal eGFR (>90 ml/min/1.73m2); 7% had 
renal impairment (eGFR < 60 ml/min/1.73m2); 32% (n=297) were underweight (BMI 
less than 18.5 kg/m2); 59% (n=551) had baseline hypoalbuminemia (serum albumin < 35 
g/L); 15% (n= 142) reported auditory symptoms either tinnitus or hearing loss at 
baseline. Among those who were tested for audiometric hearing loss (n= 481) by either 
audio booth (n= 238) or portable KUDUwave (n=243), 60% (n=289) had at least mild 
hearing loss (≥ 26dB) at any frequencies from 250 to 8,000Hz. We found that those who 
had auditory symptoms were more likely to have audiometry-confirmed hearing loss at 
baseline at any frequencies (χ2 [1]=14.69, p <0.001). About 35% of participants received 
highly standardized weekly AG exposure (i.e., ≥75 mg/kg/week, n=330). Kanamycin was 
the most common choice of AG since nine hospital sites offered kanamycin whereas only 
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one hospital site offered amikacin, and thereby the majority received kanamycin (90%, 
n=847). 
Of 936 participants, 40% (n=379) were tested for baseline and follow-up 
audiometric hearing loss and were thereby eligible to be assessed for time to developing 
audiometric hearing loss (See Table 2 for participant characteristics in each model 
development and validation cohort). 
 
Clinically-Determined Hearing Loss 
Initial AG regimens (n=420) was modified at least once in 44% of participants 
due to clinically-determined hearing loss during the 6 months of the injectable phase. 
After adjusting for age, eGFR, pre-existing composite hearing loss, AG type, and NCM 
intervention assignment, the hazard of AG regimen modification due to ototoxicity 
among the high-exposure group (≥75mg/kg/week) was 1.33 times as high as among the 
low exposure group (<75mg/kg/week, p=.006) (See Table 3 and Figure 2). 
 Further, we tested the healthcare providers’ tendency of AG regimen 
modification when they first identified clinical manifestation of AG ototoxicity. The two 
most common choices of regimen modification were reducing AG frequency (41%) and 
stopping AG (40%). In the lowest AG exposure group (<3000 mg/week), in particular, 
providers tended to stop AG when ototoxicity was observed (62%); they tended to reduce 
the frequency of AG in the intermediate (3000-4999 mg/week) and highest (5000+ 






Audiometric Hearing Loss 
Of 379 subjects who were tested with audiometry, 62.8% developed any level of 
hearing loss during the first 6-months of the intensive phase. In the final model—after 
adjusting for age, eGFR, pre-existing audiometric hearing loss, type of audiometer, AG 
type, and NCM intervention assignment—patients with high AG exposure (≥75mg/week) 
had 1.34 times higher adjusted hazard of hearing loss than those with low exposure 
(p=.038). Also, this model estimated that patients with baseline audiometric hearing loss 
had 1.71 times higher adjusted hazard of hearing loss than those with normal hearing (p 
<.001), and 1 year increased age was associated with 1.02 times increased adjusted 
hazard of hearing loss (p=.031) after all other factors held constant (see Table 3 and 
Figure 3). Last, audiometric hearing loss was more common among those who received 
kanamycin than amikacin, 58% and 5%, respectively (χ2[1]=5.33, p=.021).  
 
DISCUSSION 
This study found that the initial AG dosage is one of the key elements influencing 
the risk of AG-induced hearing loss and AG regimen modification during the DR-TB 
treatment intensive phase. According to the South African National Department of Health 
guidelines, the standard MDR-TB long-course regimen consists of one intramuscular 
injectable AG with an average dose of 15mg/kg and a maximum frequency of 5 times per 
week for at least 6 months.8 That means that, if a patient received more than 
75mg/kg/week (= 
15𝑚𝑔 𝑥 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔)𝑥 5 𝑡𝑖𝑚𝑒𝑠 𝑝𝑒𝑟 𝑤𝑒𝑒𝑘
𝑤𝑒𝑖𝑔ℎ𝑡 (𝑘𝑔)
 ) of AG, he/she received AG more 
than the average dosing suggested by the guidelines. Those who were exposed to AG 
more than 75mg/kg/week were at higher risk of AG-induced hearing loss, and that 
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thereby the risk of AG regimen reduction or discontinuation is higher than those exposed 
to AG less than 75mg/kg/week. The short-course regiment includes one intramuscular 
injectable AG with an average dose of 15mg/kg and a maximum frequency of 7 times per 
week for at least 4 months, but because the short-course regimen initiated after July 2017 
in South Africa, no patients have received AG frequency more than 5 times per week in 
this sample.  
In addition, when providers identified audiology-confirmed hearing loss or 
patients’ auditory symptoms of AG toxicity, they tended to stop AG regimen if patients 
were receiving a low dosage; while they tended to reduce AG frequency rather than dose 
if patients were receiving medium or high dosage. Other risk factors of hearing loss, such 
as advanced age and pre-existing hearing loss were also significantly associated with the 
hazard of audiometric hearing loss and the decision of AG regimen modification. These 
findings highlight the importance of not only baseline screening of hearing as a routine 
practice, but also more frequent audiometric hearing monitoring or offering a less 
ototoxic regimen for elderly patients with pre-existing hearing loss to avoid severe 
hearing deficits.  
The standardized weekly AG exposure may be considered a significant predictor 
of AG-induced hearing loss. Since excessive AG concentration is a known risk factor for 
AG ototoxicity, standardized weekly AG exposure may also be considered a proxy 
surrogate measure of AG concentration in resource-limited settings where therapeutic 
drug monitoring is impractical. Further, we expect that our findings may guide healthcare 
providers to develop personalized interventions to prevent AG-induced hearing loss in 
medically underserved settings.  
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There were several limitations in this study. There were significant missing data 
of baseline measures, which limited the power of our analysis. Particularly, missing data 
of audiograms, BMI, creatinine clearance, and CD4 count reflect a lack of adherence to 
MDR-TB treatment guidelines for ensuring that patients have baseline labs. We 
hypothesized that renal function at treatment initiation may directly influence the level of 
AG accumulation in the inner ear as AGs are excreted by glomerular filtration. However, 
the impact of renal function was underpowered due to low prevalence of renal failure and 
large missing data in this sample. We also acknowledge that as AG is a nephrotoxic 
agent, not only baseline but also follow-up measures of eGFR would contribute to the 
hazard of hearing loss. However, our analysis was not controlled for renal function as a 
time-varying exposure due to significant missing data of follow-up creatinine clearance. 
This study only explored the outcome of hearing loss up to 6-months of follow-up. While 
this is the time period of greatest incidence of AG-induced hearing loss, we assume that 
even after an intensive phase with AG discontinuation, hearing loss may progress 
because AG molecules accumulate rapidly in the interstitium but are eliminated slowly.15 
Thus, future studies need to follow patients’ hearing beyond the intensive phase of 
treatment. It is also vital to support audiological rehabilitation to improve communication 
for those who have moderate to severe hearing loss during or after the continuous phase. 
There was a possibility of unmeasured confounders. As an observational study using 
secondary data, randomization is impossible to inquire the time to develop drug toxicity 
in human study. Also, the selection of study variables was also limited to those collected 
by the parent study. Future studies should design in larger, well-defined prospective 
cohorts that include regular audiological evaluation and comprehensive history-taking. 
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Since hearing loss is one of the most common cochlea toxicities and debilitating adverse 
outcomes of AGs from MDR-TB treatment, vestibular ototoxicity, can also be 
permanent, signs and symptoms of dizziness, ataxia, or nystagmus require more attention 
in future studies. Last, due to minimal use of amikacin in this sample, this study was not 
powered to explore the impact of type of AG on hearing loss even though AG type was 
included in the final model to control for potential confounding effect. Thus, special 
caution is needed in interpretation because it can lead to potential undercoverage bias.   
In South Africa, an AG-sparing regimen, including a non-injectable anti-TB drug 
such as bedaquiline, is available for those at high risk for developing hearing loss. 
However, there are no clear guidelines for healthcare providers to screen high-risk 
individuals for practical and cost-effect allocation of an AG-sparing regimen. Therefore, 
to prevent AG ototoxicity while maximizing treatment effect, we suggest that providers 
consider calculating the standardized weekly AG exposure as a reasonable proxy measure 
of AG concentration without invasive testing.  
 
CONCLUSION 
Our analysis found significant impact of a standardized weekly AG exposure on 
AG-induced hearing loss. We additionally found that the presence of pre-existing hearing 
loss and advanced age increase the hazard of AG-induced hearing loss. Such findings 




Table 1. Study Variables and Degree of Hearing Loss 
Variable Measurement Type 
Demographics from parent dataset 
Age  Decade intervals Ordinal 
Sex Male or female Binary 
MDR-TB history Treated with AG or not Binary 
Smoking Current, former, or never  Categorical 
Alcohol use None, light, moderate, heavy Ordinal 
Poverty Both unemployed + social grant recipient  Binary 
Social grant Recipient before MDR-TB diagnosis Binary 
Employment  Unemployed before MDR-TB diagnosis Binary 
Baseline data from parent dataset 
Pre-existing audiometric 
hearing loss  
Audiometric threshold outside of the normal range 




Self-reported auditory symptoms or audiometric 
threshold outside of the normal range between -10 
and 25dB 
Binary 
HIV status Positive or negative Binary 
NRTIs Use of any NRTIs or not Binary 
CD4 (cells/mm3) <200 or higher    Binary 
Lung cavity  Present or not Binary 
eGFR (ml/min/1.73m2) <60; 60-89; or 90+  Ordinal 
Weight  In kg Continuous  
BMI (kg/m2) <18.5; 18.5-24.9; 25+  Ordinal 
Baseline data from NHLS online portal 
Serum albumin (g/L) <35 or higher Binary 
Longitudinal data from parent dataset 
AG daily dose mg per day Continuous 
AG frequency  Times per week Continuous  
AG adherence Received days per week Continuous 
Outcome: Hearing loss during injectable phase 
Audiometric hearing loss Worsened hearing threshold compared to baseline Binary 
Clinically-determined 
hearing loss 
AG regimen change due to ototoxicity confirmed by 
either audiological or clinical evaluations 
Binary 




Normal hearing: 0-25  
Mild loss: 26-40 
Moderate loss: 41-55 
Moderately-severe: 56-70 
Severe loss: 71-90 
Profound loss: 91+ 
Ordinal 
Abbreviations: AG= aminoglycoside; BMI= body mass index; CD4= cluster of differentiation 4; eGFR= 
estimated glomerular filtration rate; HIV= human immunodeficiency virus; MDR-TB= multidrug-resistant 











(n= 379) p-value 






























Smoking: N (%) 
Non-smoker  
Light smoker (<10 cigarettes/day) 










Alcohol use: N (%) 
Non-drinker 
Less than once per week 






















HIV status & CD4 count†: N (%) 
HIV negative 
HIV positive with CD4 200+ 
HIV positive with CD4 <200 












ART status among HIV-infected: N (%) 
No ART at baseline 








Previous history of DR-TB: N (%)  
New DR-TB 











Pre-existing composite HL‡: N (%) 
Normal hearing 











BMI§: N (%) 
Underweight (<18.5) 
Normal (18.5-24.9) 






















































*Age unit=years old; †CD4 count unit=cells/mm3; ‡Pre-existing composite hearing loss defined as confirmed 
by either audiometry or self-reported auditory symptoms; §BMI unit=kg/m2; ‖serum albumin unit= g/L; 
¶eGFR unit=mL/min/1.73m2 
Abbreviations: ART=Anti-retroviral therapy; CD4=cluster of differentiation 4; DR-TB=drug-resistant TB; 
eGFR=estimated glomerular filtration rate; HIV=human immunodeficiency virus; HL=hearing loss; NCM= 




Table 3. Cox Proportional Hazard Modeling on AG-induced hearing loss 


























Age (years old) 1.00 (0.99-1.01) 1.00 (1.00-1.01)  1.02 (1.01-1.03) 1.02 (1.00-1.03) 
eGFR (mL/min/1.73m2) 1.00 (1.00-1.00) 1.00 (0.99-1.00)  1.00 (0.99-1.00) 0.99 (0.99-1.00) 
Pre-existing composite HL* 








 - - 
Pre-existing audiometric HL 
Normal hearing  








Type of audiometer 
Audio booth 








































*Pre-existing composite hearing loss defined as confirmed by either audiometry or self-reported auditory symptoms. Abbreviations: AG= aminoglycoside; CI= 





















Abbreviations: KM= kanamycin; AMK= amikacin; DS-TB= drug-sensitive tuberculosis; XDR-TB= extensively drug-resistant tuberculosis  
Assessed for eligibility 
n=1279 
Excluded (n=343) 
• DS-TB (n=47) 
• (pre)XDR-TB (n=176) 
• withdrawal at baseline (n=14) 
• Not on KM or AMK (n=106) 





Included in study 
 n= 936 
Subjects with baseline audiograms 
n=482 (51.5%) 
Audiometric hearing loss cohort  
N=379 







Figure 2. Kaplan-Meier Cumulative Proportional Hazard of AG-induced Hearing Loss in 
Clinically-Determined Hearing Loss Cohort 




































329 285(44) 234(51) 208(26) 192(16) 181(11) 172(18)75+mg/kg/week
596 506(90) 450(56) 418(32) 396(22) 377(19) 369(34)<75mg/kg/week
No. at Risk:
0 30 60 90 120 150 180










































365 285(80) 241(44) 218(23) 202(16) 184(18) 177(17)Baseline HL
568 515(53) 452(63) 417(35) 395(22) 383(12) 373(35)Normal Hearing
No. at Risk:
0 30 60 90 120 150 180






Figure 3. Kaplan-Meier Cumulative Proportional Hazard of AG-induced Hearing Loss in 
Audiometric Hearing Loss Cohort 







































144 114(30) 84(30) 67(17) 57(10) 54(3) 51(4)75+mg/kg/week
235 193(42) 155(38) 138(17) 121(17) 105(16) 92(14)<75mg/kg/week
No. at Risk:
0 30 60 90 120 150 180






b. By pre-existing audiometric hearing loss 
 
 





































221 171(50) 124(47) 102(22) 84(18) 77(7) 68(10)Baseline HL
158 136(22) 115(21) 103(12) 94(9) 82(12) 75(8)Normal Hearing
No. at Risk:
0 30 60 90 120 150 180
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Setting: Many individuals being treated for drug-resistant tuberculosis (DR-TB) in 
resource-limited environments experience permanent hearing loss due to the ototoxic 
effect of injectable aminoglycosides (AGs). Despite these known risks, there is no 
practical, cost-effective means to identify those at highest risk for developing hearing 
loss. 
Objective: To develop a prediction model of AG-induced ototoxicity among patients 
initiating DR-TB treatment in South Africa. 
Design: This study used nested prospective cohort data. All participants older than 13 
years of age with confirmed DR-TB in South Africa were included. Predictors were 
collected from clinical, audiological, and laboratory evaluations conducted at the 
initiation of DR-TB treatment. The outcome of AG-induced hearing loss was identified 
from audiometric and clinical evaluation by a worsened hearing threshold compared to 
baseline. Multiple logistic regression was used to develop a prediction model. 
Results: The model predicting hearing loss at hearing frequencies from 250 to 8,000Hz 
included: standardized weekly AG exposure, HIV status with CD4 count, age, serum 
albumin, BMI, and pre-existing hearing loss. This model demonstrated reasonable 
discrimination (AUC= 0.715) and calibration (χ2[8]=6.10, p=.636). The predictive 
property of ultrahigh-frequency hearing loss—hearing frequency higher than 9,000Hz—
(AUC=0.806; χ2[8]=6.48, p=.593) and clinically determined hearing loss (AUC=0.599; χ2 
[8]=4.34, p=.825) were validated. Using a cutoff of 85% predicted the probability of 
hearing loss; the positive predictive value was 100% and the negative predictive value 
was 41%.  
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Conclusion: This model using readily available clinical data may add value in identifying 
patients with DR-TB who are at high risk of developing ototoxicity during treatment that 




Tuberculosis (TB) is now the leading cause of infectious disease-related deaths 
worldwide and is particularly common and lethal in HIV/AIDS-endemic areas such as 
South Africa.1 A growing concern in South Africa is drug-resistant TB, defined as TB 
resistant to at least one of the two most powerful first-line anti-TB drugs: rifampicin and 
isoniazid. Drug-resistant TB (DR-TB) also includes multidrug-resistant TB (MDR-TB), 
which is TB resistant to both rifampicin and isoniazid, and is an extensively drug-
resistant TB (XDR-TB), which is TB resistant to second-line anti-TB drugs: 
fluoroquinolones and injectable aminoglycosides.2 
Unfortunately, DR-TB treatment has only a 50% success rate, is costly, and is 
quite toxic.3 Hearing loss is the most debilitating adverse drug effect associated with 
second-line drugs used for DR-TB. Permanent hearing loss is primarily caused by an 
injectable aminoglycoside (AG) given during the first phase (at least 4-6 months) of DR-
TB treatment. It begins with high-frequency hearing loss with or without tinnitus, can 
progress even with discontinuation of AG treatment, and is often permanent.4,5 It causes 
social isolation, threatens quality of life, and puts employment stability and family 
prosperity at risk.6-12 Although AG-induced hearing loss is a known adverse reaction that 
occurs in 23% to 69% of patients, AG is a mainstay of DR-TB treatment recommended 
by the World Health Organization (WHO).4,5,13  
There are several risk factors that appear to aggravate AG ototoxicity. High AG 
plasma concentrations and frequent or prolonged dosing may increase risk; however, 
monitoring of drug concentrations is impossible in most resource-limited settings.4,5 The 
risk of hearing loss is impacted by HIV coinfection as a result of severe immuno-
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suppression along with antiretroviral therapy (ART): up to 70% of South African DR-TB 
patients are living with HIV.1,13,14 Both ART and anti-TB drugs may also cause renal 
impairment, which hastens ototoxicity due to decreased renal excretion of AGs.15-19 
Clinical manifestations of TB such as malnutrition and severe, disseminated 
inflammation may be associated with increased incidence of hearing loss.20-26 Pre-
existing hearing loss, prior use of ototoxic drugs for DR-TB treatment, comorbidities, 
advanced age, and substance use may increase the risk for subsequent hearing loss.27,28 
Despite these known risks, there is no cost-effective, practical means in which to 
translate this knowledge into the risk of hearing loss in DR-TB treatment to identify those 
at high risk for developing hearing loss. Thus, this study aimed to develop a prediction 
model of AG-induced hearing loss in DR-TB treatment in South Africa.  
 
METHODS 
Study Design and Setting 
This prospective cohort study used a secondary analysis nested within an ongoing 
5-year cluster-randomized trial in South Africa. The parent study investigated the effects 
of nurse case management (NCM) in improving treatment outcomes in individuals with 
DR-TB. Data were collected across 10 public TB hospitals in the Eastern Cape and 
KwaZulu-Natal provinces. According to Farley et al., these hospitals were randomized by 
location and size to a nurse case management intervention from a pilot study.29 Full 




The following patients were included: (1) all patients 13 years of age and older; 
(2) with microbiologically confirmed DR-TB using cartridge-based Xpert®; (3) those 
enrolled across 10 study sites; (4) those enrolled from November 2014 to June 2017; and 
(5) those who signed informed consent within seven days of treatment initiation. The 
following patients were excluded: (1) those receiving neither intramuscular kanamycin 
nor amikacin injection; and (2) those confirmed for drug-sensitive TB, XDR-TB, and pre-
XDR—TB resistant to either fluoroquinolones or aminoglycosides—from baseline drug 
sensitivity tests that resulted during the first 6-months’ injectable phase of treatment.    
 
Predictors and Measures 
The following variables were abstracted from the parent study’s baseline data: (1) 
demographics and medical history including previous TB history, comorbidities, 
prescribed medications, and substance use; (2) presence of lung cavities on chest x-ray at 
DR-TB diagnosis; (3) serum creatinine levels to calculate estimated glomerular filtration 
rate (eGFR) for renal function; (4) HIV infection history including use of any ARTs and 
CD4 count; and (5) nutritional status measured by body mass index (BMI). 
Since the parent study did not collect serum albumin levels, baseline albumin 
results were collected from the South African National Health Laboratory System 
(NHLS) online portal as a routine laboratory test for DR-TB treatment. Since no 
instrument exists for measuring poverty in South Africa, the conceptual definition of 
social deprivation30 was used to select appropriate study variables to operationalize 
poverty in this study. South African social grants are given not only to the poor but also 
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to the elderly, the disabled, or caregivers of a child with a disability.31 Thus, poverty was 
measured by a combination of social grant and employment status prior to MDR-TB 
diagnosis in the context of interdependency between TB and poverty in South Africa.32,33  
The following variables were abstracted from the parent study’s baseline and 
monthly follow-up data during the injectable phase: (1) DR-TB treatment regimen 
including type of AG, AG dose, frequency, and adherence; (2) DR-TB confirmation test 
results including sputum culture and drug sensitivity tests; and (3) auditory symptoms 
(i.e., hearing loss and tinnitus) and audiometric hearing evaluation results. Weekly 
measured regimen adherence and dosing information were used to calculate cumulative 
(or weekly) AG exposure per body weight (this study called standardized weekly AG 
exposure) =   
prescribed  daily AG dose (mg) x frequency of dosing over week (times per week)
weight (kg)
.  
Hearing was tested monthly by audiometry to establish the lowest intensity of sound (= 
hearing threshold) in decibels (dB) that the person could hear at frequencies ranging 
from 250 to 8,000 Hz.28 Then, the level of hearing threshold for each frequency was 
transferred to degree of hearing loss to define outcome of hearing loss. The degree of 
hearing loss is categorized in Table 1.  
This study defined pre-existing composite hearing loss as: (1) a hearing threshold 
outside of the normal range between -10 and 25dB in one or both ears at any frequencies 
in the range from 250 to 8,000 Hz, tested by either standard audio booth or computer-
based portable audiometer (KUDUwave®) at baseline audiometry (aka pre-existing 
audiometric hearing loss); or (2) self-reported auditory symptoms including tinnitus or 
hearing loss at baseline. The outcomes of AG-induced hearing loss were further defined 
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as: clinically-determined hearing loss resulting in a change in treatment (i.e., reduced or 
stopped AG) due to ototoxicity confirmed by either audiological evaluation or self-
reported symptoms of hearing loss or tinnitus; or (2) audiometric hearing loss defined as 
a deterioration of at least one category of hearing loss compared to baseline hearing in the 
same range of frequencies in one or both ears. 
 
Ethical Approval  
The parent study was approved by the Provincial Health Research Committee of 
the Eastern Cape and KwaZulu-Natal Provincial Departments of Health in South Africa. 
The parent study and this sub-study were both approved by the Biomedical Research and 
Ethics Committee of the University of KwaZulu-Natal in South Africa and the 
Institutional Review Board of the Johns Hopkins Medical Institutions (NA_00078899 / 
CIR00024657).   
 
Statistical Analysis for Model Development and Validation 
A multivariable logistic regression model was used to develop prediction models 
by introducing the following predictors: standardized weekly AG exposure, HIV status, 
use of ART, CD4 count, presence of lung cavities, renal impairment (eGFR), BMI, serum 
albumin, pre-existing composite hearing loss, age, sex, comorbidities, previous TB 
history, poverty, smoking, and alcohol use. Bivariate analyses using all potential 
variables were conducted initially to guide selection of predictors and the final model. 
Non-significant variables were excluded to eliminate variables that were not predictive or 
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highly collinear. All variables in the final model met the assumptions for proportional 
hazards.  
Area under receiver operating characteristics curve (AUC) and Hosmer-
Lemeshow χ2 goodness-of-fit test in a multivariable logistic regression were used as the 
metrics to assess the model’s accuracy including discrimination and calibration, 
respectively. The AUC and Hosmer-Lemeshow χ2 goodness-of-fit test were repeated with 
the remainder sample (i.e., data not used for model development) to test predictive 




Overall Descriptive Findings 
Of the 1,279 participants enrolled in the parent study, 936 were eligible for the 
present study (Figure 1). Mean age was 36.19 (SD=11.05) years, 54% were male, 48.5% 
were unemployed before DR-TB registration, 75% were HIV coinfected, 41% had a prior 
history of drug-sensitive TB, and only 5% had a prior history of DR-TB infection treated 
with 2nd line injectable anti-TB drugs. In terms of nutritional status, 32% (n=296) were 
underweight (i.e., BMI less than 18.5kg/m2) and 59% (n=551) had hypoalbuminemia 
(i.e., serum albumin < 35 g/L). Of 697 HIV-coinfected participants, 46% were taking 
ART, and 34% were severely immunosuppressed (CD4 count < 200 cells/mm3) at 
baseline.  
Of 936 participants, 51% (n=481) were tested for baseline hearing by either audio 
booth (n= 238) or portable KUDUwave (n=243); 60% (n=289) had at least mild hearing 
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loss (≥ 26dB) at any frequencies between 250 and 8,000Hz. Additionally, 157 of 481 
participants were tested for ultrahigh-frequency hearing (i.e., hearing threshold from 
9,000Hz up to 16,000Hz). Of those, 74% (n=116) had at least mild hearing loss at 
frequencies from 250 to 16,000Hz and 67% (n=105) had ultrahigh-frequency hearing loss 
ranging from 9,000 to 16,000Hz. One hundred forty-two of 936 (15%) reported auditory 
symptoms at baseline, and those who had auditory symptoms were more likely to have 
audiometry-confirmed hearing loss at baseline at any frequencies from 250 to 8,000Hz 
(χ2 [1]= 14.69, p <0.001).  
Among those who were tested for baseline hearing threshold (n=481), 379 were 
tested for follow-up audiometric evaluations during the first 6 months of injectable 
treatment and of those, 114 were tested for ultrahigh-frequency audiometry (i.e., for 
frequencies from 250 to 16,000Hz). During this follow-up period, 63% (n=238) 
developed any level of hearing loss at frequencies from 250 to 8,000Hz; of those, 56% 
(n=134) who developed audiometric hearing loss experienced AG regimen modification 
either discontinued or reduced AG treatment due to ototoxicity.  
To develop prediction models, we selected data from 265 participants those who 
were tested for frequencies from 250 to 8,000Hz. The subset of 114 participants, who had 
been examined for ultrahigh-frequency hearing threshold, were used to validate the 
model’s function to predict hearing loss separately at frequencies from 250 to 8,000Hz 
and also from 9,000 to 16,000Hz. We also validated the model using 671 participants 
who were not included in the model development cohort and did not undergo audiometric 
evaluation to test whether the developed model could predict the risk of modification of 
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AG regimen that resulted from ototoxicity based on clinical judgement. See Table 2 for 
participant characteristics in each model development and validation cohort.  
 
Model Development and Validation  
In the model development cohort of 265 participants, 62% (n=165) developed 
audiometric hearing loss. The selection of predictors was initially guided by statistically 
significant bivariate models, including the following: age (p= .006), age category by 
decade (p= .022), type of AG (p= .023), eGFR (p= .016), serum albumin (p= .033), 
previous TB history (p= .016), and pre-existing composite hearing loss (p= .012). We 
selected clinically significant weekly AG exposure and HIV status with CD4 counts as 
core predictors (AUC= 0.572; 95% CI= 0.497-0.647). Adding age, serum albumin, BMI, 
and pre-existing composite hearing loss (full model) led to a better prediction of hearing 
loss in discrimination (AUC= 0.715, 95% CI= 0.635-0.794) and calibration (χ2 [8]= 6.10; 
p= 636). The final model of hearing loss with odds ratios is shown in Table 3. Using a 
cutoff of 85% predicted the probability of hearing loss; the positive predictive value of 
this model was 100%; the negative predictive value was 40.91% (See Table 4 and Figure 
2-A). 
In the audiometric hearing loss validation cohort (n=114), 64% (n=73) developed 
hearing loss at frequencies from 250 to 8,000Hz and 82% (n=93) developed hearing loss 
from 9,000 to 16,000Hz. We conducted validation tests at frequencies from 250 to 
8,000Hz, and the developed model demonstrated comparable discrimination (AUC= 
0.686, 95% CI= 0.564-0.807) and calibration (χ2 [8]=8.03; p=0.431) (Table 4 and Figure 
2-B). Further, in the ultrahigh-frequency audiometric validation cohort, the predictive 
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accuracy was improved in discrimination (AUC= 0.806, 95% CI= 0.689-0.923) and 
calibration (χ2 [8]= 6.48; p= 0.593), signifying the models’ good performance in 
predicting ultrahigh-frequency hearing loss at frequencies from 9,000 to 16,000Hz (Table 
4 and Figure 2-B). In the clinically-determined hearing loss validation cohort, we tested 
predictive property as to whether the model could predict the modification of AG 
regimen (i.e., reduced or discounted AG regimen) due to ototoxicity as an outcome, 
representing reasonable discrimination (AUC= 0.599, 95% CI= 0.543-0.655) and 
calibration (χ2 [8]= 4.34; p= .825). (Table 4 and Figure 2-D). 
 
DISCUSSION 
We developed and validated a simple prediction tool that can be used to estimate 
DR-TB patients’ risk of hearing loss for the first 6 months of AG treatment. Although 
ototoxicity is dose-dependent, our model suggests that not only initial dosing of AG 
regimen but also a baseline status of malnutrition (i.e., underweight and 
hypoalbuminemia), immunosuppression (i.e., HIV coinfection with low CD4 count), 
advanced age, and pre-existing composite hearing loss were highly associated with the 
risk of AG-induced hearing loss. We also conducted model validation tests in different 
clinical settings of utilizability of audiometric evaluation because our model was 
purposively developed using audiometric data to test clinical standard frequencies from 
250 to 8,000Hz. 
The validation of our model in ultrahigh-frequency audiometric data, in particular, 
found that this model may also be useful to predict early manifestations of AG 
ototoxicity. Such findings are critically important because typical manifestations of 
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cochleotoxicity begin with ultrahigh-frequency hearing loss with or without tinnitus, 
which may not be clinically apparent, and are often undetected by standard audiometry 
testing frequency below 9,000Hz.4,35 The validation in the clinically-determined hearing 
loss cohort demonstrated minimal predictive ability in discriminating those at higher risk 
in incompletion of initial AG regimen due to ototoxicity without audiometric evaluation. 
Such finding augments generalizability of the model to clinical sites where regular 
audiometry is impractical. We selected a cutoff of 85% in the development cohort with 
the goal of screening highest specificity, leading to highest positive predictive value. 
Thus, healthcare providers can triage patients whose predictive probability is higher than 
85% to AG-sparing regimen, which enhances the practicality of the model in clinical sites 
where an AG-sparing regimen is insufficient.  
This study has several limitations. A relatively small sample size was used for 
model development and validation. We calculated the sample size based on the ratio of 
the outcome event to the number of predictors, referred to as the events per variable 
(EPV).36,37 The rule of thumb is that multivariable logistic models should be used with a 
minimum of 10-outcome EPV, while an EPV of more than 20 is ideal.38 The final sample 
size for model development according to an EPV of 20 was 320 as the number of 
variables of the prediction model was 16; we used 265 samples to develop models. Since 
small sample size in developing a prediction model reduces predictive accuracy and 
increases variance in the validation of model performance, the implication of our models 
needs special caution in clinical settings. Although we acknowledge that ultrahigh-
frequency is more clinically useful for early detection of ototoxicity, data for those who 
were tested for ultrahigh frequency were not used to develop but to validate the model 
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due to the small sample size. Since this was a secondary data analysis, the selection of 
study variables was limited to those collected by the parent study. Since the parent study 
was not designed to inquire about hearing loss from DR-TB treatment, other risks for 
hearing loss, such as noise exposure, non-sensorineural hearing loss, and family history 
of ototoxicity were not collected. However, the impact of these factors on baseline 
hearing loss was assessed with audiometry in the model development cohort. Additional 
studies performed in larger, well-defined prospective cohorts and that include regular 
audiometric evaluation and comprehensive history-taking would be useful to better 
validate these findings.  
This study included samples from both intervention and control sites of the parent 
study. We acknowledge that there might be potential threats of intervention effects 
because NCM intervention sites may be more likely to facilitate hearing screening and 
modification of AG regimen since NCMs are more involved in inpatient care. Although 
the audiometric validation cohort consisted of more NCM intervention sites, this model 
was not adjusted for assignment of intervention site to maximize generalizability of the 
model. Since BMI and audiometry data were collected by hospital staff members who 
had not been trained by the parent study, measurement errors might occur equally across 
all sites. These programmatic measurements were used by healthcare providers to make 
clinical decisions including TB medication dosing, so they are clinically relevant. 
Despite these limitations, this study has many strengths. This is the first study to 
develop a prediction model of AG-induced hearing loss among DR-TB-infected 
individuals. In 2016, the WHO released new treatment guidelines offering for the first 
time a shortened MDR-TB treatment of 9-12 months.83 The regimen includes 7 drugs; 
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AGs are given at least for the first 4 months.83 An AG-sparing regimen is reserved for 
those with substantial risk of hearing loss.2 Today that risk is based solely on clinical 
expertise without a tested and validated measure to support those decisions. If the risk of 
AG-induced hearing loss can be estimated at treatment initiation, healthcare providers 
can triage high-risk patients to newer, less ototoxic drugs such as bedaquiline, that, while 
more costly, will eliminate such hearing loss. In July 2017, the South African Department 
of Health initiated an AG-sparing regimen that includes bedaquiline, and because these 
study data were collected from November 2014 to June 2017, the clinician’ selection of 
regimen in this study is minimally influenced by bedaquiline availability. In most 
resource-limited countries, TB programs are suffering from financial constraints to offer 
an AG-sparing regimen. Thus, our prediction model may be used to avoid this 
unnecessary adverse event and guide clinical decision-making. Our prediction model was 
developed by using existing clinical data collected based upon South African national 
guidelines for DR-TB management. Thus, additional lab tests or clinical evaluations were 
not required to use the developed model. The study addresses a critical need to predict 
risk for developing hearing loss in a low-resource setting where therapeutic drug 
monitoring is not feasible. Although we expect that predicting hearing loss risk will 
reduce ototoxic drug use for those at highest risk and will thereby reduce hearing loss, 
other physio-psychological and socioeconomic factors would influence the outcome of 
hearing loss since each individual is unique. To use this model, providers must consider 
the impact of other factors unmeasured in this model on AG-induced hearing loss. 
Finally, cost-effectiveness of prediction model is needed to quantify the gains or setbacks 
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in DR-TB treatment outcomes by prioritizing the allocation of more expensive AG-
sparing regimen based on the model’s predictive properties. 
 
CONCLUSION 
Our model suggests that patients’ initial AG dosing, nutritional status, HIV status, 
and pre-existing hearing loss at baseline are highly associated with AG-induced hearing 
loss. The findings have the potential to be very high-impact (informing treatment 
guidelines) and, moreover, are readily feasible, as the study used existing, quality-assured 
data. The findings will contribute to improve not only the management of DR-TB and 
severe clinical complications but also the physical and environmental influences at 
baseline on impaired hearing and fill key gaps in personalized interventions to prevent 
drug-induced hearing disability in underserved populations.
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Table 1. Degree of Hearing Loss  




loss range39  
(dB) 
Hearing loss range in this 
study  
(dB) 
Normal –10 to 15 
-10 to 25 
(Slight) 16 to 25 
Mild 26 to 40 26 to 40 
Moderate 41 to 55 41 to 55 
Moderately severe 56 to 70 56 to 70 
Severe 71 to 90 71 to 90 
Profound 91+ 91+ 
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Smoking: N (%) 
Non-smoker  
Light smoker (<10 cigarettes/day) 













Alcohol use: N (%) 
Non-drinker 
Less than once per week 

























HIV status & CD4 count†: N (%)  
HIV negative 
HIV positive with CD4 ≥200 
HIV positive with CD4 <200 
















ART status: N (%) 
No ART at baseline 










Previous history of DR-TB: N (%) 
New DR-TB 














Pre-existing composite HL‡: N (%) 
Normal hearing 














BMI§: N (%) 
Underweight (<18.5) 
Normal (18.5-24.9) 































Unknown 70 (26.42) 13 (11.40) 122 (18.18) 
































*Age unit=years old; †CD4 count unit=cells/mm3; ‡Pre-existing composite hearing loss defined as confirmed 
by either audiometry or self-reported auditory symptoms; §BMI unit=kg/m2; ‖serum albumin unit= g/L; 
¶eGFR unit=mL/min/1.73m2 
Abbreviations: ART=Anti-retroviral therapy; BMI=body mass index; CD4=cluster of differentiation 4; 
DR-TB=drug-resistant tuberculosis; eGFR=estimated glomerular filtration rate; HIV=human immuno-
deficiency virus; HL=hearing loss; NCM=nurse case management; SD=standard deviation. 
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HIV status & CD4 count (cells/mm3) 
HIV negative 
HIV positive with CD4 200+ 









Serum Albumin (g/L) 1.02 (0.97-1.08) .486 
Pre-existing composite hearing loss* 1.17 (0.55-2.46) .685 
Full model 
log odds of hearing loss = 0.045 (age) – 0.96 (BMI: 18.5-24.9) – 1.27 (BMI: ≥25) – 
0.41 (weekly AG exposure: 60-74.9) + 0.27 (weekly AG exposure: ≥75) + 0.53 (HIV+ 
with CD4 ≥ 200) + 0.71 (HIV+ with CD4 < 200) + 0.02 (serum albumin) + 0.15 (pre-
existing composite hearing loss) – 1.61 
*Pre-existing composite hearing loss defined as confirmed by either audiometry or self-reported auditory 
symptoms  
Abbreviations: AG= aminoglycoside; BMI= body mass index; CD4= cluster of differentiation 4; CI= 




Table 4. Model Performance in Predicting AG-induced Hearing Loss 
 
Audiometric hearing loss 
in development cohort 
(250-8,000Hz) 
Audiometric hearing loss 
in validation cohort  
(250-8,000Hz) 
High-frequency hearing 





AUC (95% CI) 0.715 (0.635-0.794) 0.686 (0.564-0.807) 0.806 (0.689-0.923) 0.599 (0.543-655) 
Hosmer-Lemeshow χ2 [8] = 6.10 (p= .636) χ2 [8] = 8.03 (p= .431) χ2 [8] = 6.48 (p= .593) χ2 [8] = 4.34 (p=.825) 
Sensitivity*(%) 9.90 14.75 70.13 0.00 
Specificity* (%) 100.00 90.63 87.50 100.00 
PPV* (%) 100.00 75.00 96.43 . 
NPV* (%) 40.91 35.80 37.84 59.95 
*Using cutoff of 85% predictive probability. 
Abbreviations: AUC=area under receiver operating characteristic curve; PPV=positive predictive value; NPV=negative predictive value. 
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Abbreviations: KM= kanamycin; AMK= amikacin; DS-TB= drug-sensitive tuberculosis; XDR-TB= extensively drug-resistant tuberculosis  
Excluded (n=343) 
• DS-TB (n=47) 
• (pre)XDR-TB (n=176) 
• withdrawal at baseline (n=14) 
• Not on KM or AMK (n=106) 





Follow-up audiometric evaluations tested frequencies 
from 250 to 8,000H; N=379 




Audiometric hearing loss 
(250-8,000Hz) 




validation cohort  
N=114 
Clinically-determined 
hearing loss validation 
cohort  
N=671 
Audiometric frequency tested 
from 250 to 16,000Hz 
N=114 
Subjects with baseline audiograms 
n=482 (51.5%) 
Assessed for eligibility 
n=1279 
Included in study 
 n= 936 
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Figure 2. Receiver-Operating-Characteristic (ROC) Curves for AG-induced Hearing Loss 
A. Audiometric hearing loss development cohort: AUC= 
0.715 
B. Audiometric hearing loss validation cohort (250-
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C. High-frequency hearing loss validation cohort (9,000Hz-
16,000Hz): AUC= 0.806 
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CHAPTER 7: DISCUSSION 
INTRODUCTION 
The goal of this dissertation was to estimate the risk of AG-induced hearing loss 
for MDR-TB-infected individuals in the Eastern Cape and KwaZulu-Natal provinces of 
South Africa. To our knowledge, this study is the first to explore the impact of 
cumulative AG exposure as a surrogate measure of AG concentrations on the risk of AG-
induced hearing loss and to develop and validate a prediction model to calculate the risk 
of AG-induced hearing loss at the initiation of MDR-TB treatment.  
This chapter presents a summary of the results of this study presented within the 
framework of the two study aims. Findings are discussed for each aim of the study 
separately followed by the strengths and limitations, and then the implications of the 
study’s findings are described. Finally, suggestions for future research are discussed.  
 
The specific aims of this study were: 
Aim 1: To explore the prognostic impact of cumulative AG exposure on AG-induced 
hearing loss in MDR-TB patients following initiation of injectable-containing 
multidrug therapy for MDR-TB. 
Aim 2: To develop a prediction model of AG-induced hearing loss in MDR-TB 
treatment. 
SUMMARY OF FINDINGS 
Aim 1 
This study found that the initial AG dosage is one of the key elements influencing 
the risk of AG-induced hearing loss and AG regimen modification during the DR-TB 
treatment intensive phase. We found that those who were exposed to AG more than 
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75mg/kg/week—the average dosage that the MDR-TB treatment guidelines suggested—
were at higher risk of AG-induced audiometry-confirmed hearing loss, and that thereby 
the risk of AG regimen reduction or discontinuation was higher than those exposed to AG 
less than 75mg/kg/week (aHR=1.34, p=0.38). Since excessive AG concentration is a 
known risk factor for AG ototoxicity, standardized weekly AG exposure may also be 
considered a proxy surrogate measure of AG concentration in resource-limited settings 
where therapeutic drug monitoring is impractical. We expect that our findings may guide 
DR-TB providers to develop personalized interventions to prevent AG-induced hearing 
loss in medically underserved settings. Further, initial AG dosage was a matter of clinical 
judgement of regimen adjustment. In cases where AG ototoxicity was detected either by 
audiological evaluation or by the presence of auditory symptoms of AG toxicity, DR-TB 
providers tended to stop the AG regimen if patients were receiving low dosage (< 3000 
mg/week), while they tended to reduce AG frequency rather than the daily dose if 
patients were receiving medium or higher dosage (≥ 3000mg/week). Further studies are 
warranted to evaluate AG concentration between reducing frequency versus a daily dose 
in this population to maximize therapeutic efficacy and minimize adverse effects.   
Other risk factors of hearing loss, such as advanced age and pre-existing hearing 
loss, were also significantly associated with the hazard of audiometry-confirmed hearing 
loss and the decision of AG regimen modification. This finding weighted not only 
practical but also policy-level concerns because, as described in Chapter 3, a high 
prevalence of pre-existing hearing loss and potential presbycusis was found in this study 
population. These findings highlight the importance of not only baseline screening of 
hearing as a routine practice, but also more frequently repeated audiometric hearing 
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monitoring. Also, offering a less ototoxic regimen for elderly patients with pre-existing 
hearing loss should be considered to avoid severe hearing loss.  
 
Aim 2 
In this aim, we developed and validated a predictive model that can be used to 
calculate the probability of risk of hearing loss at clinical standard frequencies from 250 
to 8,000Hz for the first 6 months of AG treatment among DR-TB patients. Although 
ototoxicity is dose-dependent, our model suggests that not only the initial dosage of AG 
regimen but also the baseline status of the following factors were highly impactful in 
predicting the incidence of hearing loss: malnutrition (i.e., underweight and 
hypoalbuminemia), immunosuppression (i.e., HIV coinfection with low CD4 count), 
advanced age, and pre-existing hearing loss. This model demonstrated reasonable 
discrimination (AUC=0.715) and calibration (χ2[8]=6.10, p=.636). We also validated that 
it becomes more practical and generalizable to expand this model based on the 
availability of audiometric evaluation in different clinical situations. The validation with 
the audiometric data in ultrahigh frequencies (i.e., ≥ 9,000Hz), in particular, found 
clinical potentials that this model may also be useful to predict early manifestations of 
AG ototoxicity (AUC=0.806; χ2[8]=6.48, p=.593). Such findings are practically 
meaningful because typical manifestations of cochleotoxicity begin with ultrahigh-
frequency hearing loss, which may not be clinically apparent and are often undetected by 
standard audiometry testing frequencies below 9,000Hz.2,3 In the clinical settings where 
audiometric evaluation is impossible, this model may be utilizable to discriminate those 
at higher risk in incompletion of the initial AG regimen due to ototoxicity without 
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audiometry, which was validated in the clinically-determined hearing loss cohort 
(AUC=0.599; χ2 [8]=4.34, p=.825). This model represented a perfect positive predictive 
value (100%) at a cutoff of 85%. Thus, healthcare providers can triage patients whose 
predictive probability is higher than 85% to an AG-sparing regimen, enhancing the 
practicality of the model in clinical sites where an AG-sparing regimen is insufficient.  
 
STRENGTHS AND LIMITATIONS 
A major strength of this dissertation is that it is the first study to estimate the risk 
of AG-induced hearing loss for MDR-TB-infected individuals, leading to development of 
a clinically utilizable AG-induced hearing loss prediction model. The WHO recommends 
that an AG-sparing regimen is reserved for those with substantial risk of hearing loss.4 
However, there is no practical tools to screen those at highest risk for developing AG-
induced hearing loss, and thereby that risk is determined by the presence of pre-existing 
hearing loss or providers’ clinical expertise, even without audiological evaluations. If the 
risk of AG-induced hearing loss can be estimated at treatment initiation by using this 
predictive model, healthcare providers can triage high-risk patients to AG-sparing 
regimens. In addition, our prediction model was developed by using existing clinical data 
collected based upon South African national guidelines for DR-TB management. As a 
result, additional lab tests or clinical evaluations were not required to use this model. This 
prediction model would be more useful in a low-resource setting in terms of filling the 
gaps in personalized interventions to prevent hearing disability where AG-sparing 
regimens are insufficient. Further, this study suggested that standardized weekly AG 
exposure may be a reasonable surrogate measure of AG concentration, especially where 
 
179 
therapeutic drug monitoring is not feasible. Our findings suggest that DR-TB providers 
should closely monitor AG ototoxicity, especially for those who are receiving AG more 
than 75mg/kg/week because they are exposed to more than the average dosage that the 
MDR-TB treatment guidelines suggest.  
We acknowledge that this study has several limitations. First, selection of study 
variables was limited to those collected by the parent study. Since the parent study was 
not designed to inquire about hearing loss from DR-TB treatment, other risks for hearing 
loss, such as noise exposure, non-sensorineural hearing loss, and a family history of 
ototoxicity, were not collected for this sub-study. However, the impact of these factors on 
pre-existing hearing loss was assessed by both audiological and clinical evaluations. 
A relatively small sample size was used for prediction model development and 
validation. We evaluated the sample size based on the ratio of the outcome event to the 
number of predictors, referred to as the events per variable (EPV).5,6 The rule of thumb is 
that a minimum of 10-outcome EPV should be used in multivariable logistic models, 
while an EPV of more than 20 is ideal.7 The final sample size for model development 
according to an EPV of 15 was 240 and an EPV of 20 was 320 as the number of variables 
of the prediction model was 16; we used 265 samples to develop models. Since a small 
sample size in developing a prediction model reduces predictive accuracy and increases 
variance in the validation of model performance, the implication of our models needs 
special caution in clinical settings. Although we acknowledge that ultrahigh-frequency is 
more clinically useful for early detection of ototoxicity, the model was not developed 
with ultrahigh-frequency audiometric data due to the small sample size. Therefore, 
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further validation and refinement of the prediction model to estimate ultrahigh-frequency 
hearing loss must be considered.  
This study included samples from both the NCM intervention and control sites of 
the parent study. We acknowledge that there might be potential threats of intervention 
effects because the NCM intervention sites may be more likely to facilitate hearing 
screening and modification of AG regimen since NCMs are more involved in inpatient 
care. An NCM interaction effect was found in the survival analysis because the adjusted 
hazard of audiometric hearing loss in NCM intervention sites was 1.41 times higher than 
in the control sites (p=.032). Although the audiometric validation cohort consisted of 
more NCM intervention sites, the prediction model was not adjusted for assignment of 
the intervention site to maximize generalizability of the model. Since several study 
variables, such as BMI and audiometry data, were collected by hospital staff members 
who had not been trained by the parent study, measurement errors might occur equally 
across all sites. These programmatic measurements were used for clinical decisions 
including TB medication dosage, so they are clinically relevant. 
Due to significant missing data of baseline measures, the power of our analysis 
was limited. Particularly, missing data of audiogram, creatinine clearance (or eGFR), and 
CD4 count reflects a lack of adherence to MDR-TB treatment guidelines for ensuring that 
patients have baseline labs. We hypothesized that baseline renal function may be a 
significant predictor in the prediction model, but the impact of renal function was 
underpowered due to the low prevalence of renal failure and large missing data in this 
sample. For this study, missing height was imputed using the mean height for those with 
a height by sex and age categories. We also acknowledge that since AGs are nephrotoxic 
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agents, not only baseline but also follow-up measures of creatinine clearance would 
contribute to the risk of AG-induced hearing loss. However, our analysis was not 
considered renal function as a time-varying exposure due to significant missing data of 
follow-up creatinine clearance. Furthermore, as an observational study using secondary 
data, there was also the possibility of unmeasured and uncontrolled confounders because 
randomization is impossible to inquire the time to developing drug toxicity in human 
study. 
Finally, this study only explored the outcome of hearing loss up to 6 months of 
follow-up. While this is the time period of greatest incidence of AG-induced hearing loss, 
hearing loss may progress even after AG discontinuation because AG molecules 
accumulate rapidly in the interstitium but are eliminated slowly.8 Thus, future studies 
need to follow patients’ hearing beyond the intensive phase of treatment. 
 
IMPLICATIONS  
There are far-reaching implications from this study for healthcare providers, 
policy makers, and researchers. South Africa has made tremendous strides in improving 
DR-TB treatment including introduction of new regimens such as 9-month short-course 
regimens or injection-sparing regimens. The developed AG-induced hearing loss 
prediction model (discussed in Chapter 6) may be useful to allocate AG-sparing regimens 
cost-effectively in clinical sites where an AG-sparing regimen is insufficient. Predictors 
in the model were selected from existing clinical data collected based upon South African 
national guidelines, so there is no need to conduct additional lab tests or clinical 
evaluations to use the developed model. Since this model represented 100% positive 
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predictive value at a cutoff of 85%, healthcare providers can prioritize patients whose 
predictive probability is higher than 85% to an AG-sparing regimen. Although we expect 
that predicting hearing loss risk will reduce ototoxic drug use for those at highest risk and 
will thereby reduce hearing loss, other physio-psychological and socioeconomic factors 
would influence the outcome of hearing loss since each individual is unique. 
 This study warrants an urgent awareness of the fact that the incidence of AG-
induced hearing loss in South Africa (62.8%) is much higher than other countries, such as 
the United States (13%),9 the Netherlands (18%),10 the United Kingdom (28%),11 and 
India (10–25%).12-14 There are several possible explanations for this finding. Financial 
considerations may, in part, explain the higher incidence of AG-induced hearing loss in 
resource-limited countries than in high-resource countries. As discussed in Chapter 4, the 
high burden of HIV coinfection in South Africa may be one of the reasons for the 
significantly higher incidence of AG-induced hearing loss.15 HIV coinfection leads to 
higher risk of otologic opportunistic infections, such as seborrheic dermatitis of the 
external ear, otitis externa with otomycosis, serous otitis media, causing acute or chronic 
conductive hearing loss before or during AG treatment media.16-18 Also, because HIV-
infected individuals with severe immunosuppression have increased levels of oxidative 
DNA damage19 that accelerate hair cell damage, frequent systematic hearing monitoring 
and repeated measure of CD4 counts during the intensive phase of treatment are strongly 
suggested. Chapter 3 found that not only the incidence of hearing loss but also the 
prevalence of pre-existing hearing loss was substantially higher in this study setting as 
the prevalence of pre-existing audiometric hearing loss was 60%. Pre-existing hearing 
loss was more prevalent among those who were 50 years of age and older and had 
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previous AG exposure. Since conductive hearing loss was inconsistently evaluated only 
at several sites, pre-existing hearing loss must be screened and treated by comprehensive 
audiological assessment, including audiometry, tympanometry, and otoscopy. 
This study suggests the need to evaluate hospital and provider adherence to 
national guidelines of audiometric evaluation for those are on injectable-containing 
regimens for DR-TB treatment. The South African Department of Health MDR-TB 
guidelines instruct that audiometry should be performed prior to initiation of treatment 
and repeated at least monthly throughout the intensive phase of treatment. However, this 
study (in Chapter 3) found that only 51% of study participants’ baseline hearing was 
tested as a routine practice. What is worse is that, of those tested for baseline audiometric 
hearing, only 78.8% were tested for follow-up hearing at least once during the intensive 
phase. The availability of on-site audiologists and well-functioning audiometers at TB 
hospitals must be audited on a regular basis to make early detection of AG-induced 
hearing loss possible. Further, additional financial support is required to maintain regular 
audiometric evaluation a continuous phase of treatment because ototoxicity may worsen 
even after AG discontinuation. Also, audiological rehabilitation is needed to improve 
communication skills and quality of life for those who have moderate to severe hearing 
loss during or after the continuous phase of treatment. 
It is also critical to understand that poverty and other social determinants of health 
play a significant role in hearing loss from DR-TB treatment. Since no instrument exists 
for measuring poverty in South Africa, the conceptual definition of social deprivation20 
was used to select appropriate study variables to operationalize poverty in this study. 
South African social grants are given not only to the poor but also to the elderly, the 
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disabled, or to caregivers of a child with a disability.21 Thus, poverty was measured by a 
combination of social grant and employment status prior to MDR-TB diagnosis in the 
context of interdependency between TB and poverty in South Africa.22,23 However, since 
measurement of poverty was not validated, the combination of social grant and 
unemployment status may not precisely calibrate patients’ poverty levels in this study. 
Most patients with MDR-TB experience some level of poverty, so patients who already 
have grant access may already have social networks that connect them to this resource. 
Therefore, it is critical for policy makers to design government support systems that are 
accessible for DR-TB patients to maintain their treatment and to optimize health 
outcomes.  
 
RECOMMENDATIONS FOR FUTURE RESEARCH 
There is a need for external validation and refinement of the prediction model to 
achieve better generalizability by using a larger sample size and well-defined prospective 
cohorts, which include regular audiometric evaluation and comprehensive history-taking. 
It also is necessary to follow patients’ hearing beyond the intensive phase of treatment, 
because hearing loss may progress with AG discontinuation even after the intensive 
phase. In addition, cost-effectiveness of the prediction model is needed to quantify the 
gains or setbacks in DR-TB treatment outcomes by prioritizing the allocation of more 
expensive AG-sparing regimen based on the model’s predictive properties. Further, 
additional observational research or clinical trials are warranted to evaluate the 
importance of audiological rehabilitation on improving communication skills and quality 
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of life for those who have moderate to severe hearing loss during or after the continuous 
phase of TB treatment. 
A comprehensive measure of nutritional status must be considered for future 
studies because it is a significant predictor of AG-induced hearing loss. In both the 
bivariate Cox regression model and the logistic model, the impact of baseline 
underweight (i.e., BMI < 18.5 g/m2) was significantly associated with the risk of AG-
induced hearing loss, and adding BMI and albumin level significantly improved the 
predictive property of the model. However, this study was limited to inquiry regarding 
the impact of nutritional status on AG-induced hearing loss because only BMI and serum 
albumin were introduced in the model. Since AG molecular concentration is influenced 
by body size,24 future studies may need to include the following physiological 
parameters: (1) body size measured by anthropometric parameters such as body weight, 
BMI, arm/waist/hip/calf circumferences, and triceps/subscapular skinfold; or (2) body 
composition measured by bioelectrical impedance such as fat mass, fat-free mass, muscle 
mass, fat area, muscle area, total body water, intracellular water, and extracellular water, 
etc. In addition, future observational studies or clinical trials should be considered to 
offer nutritional supplements for malnourished patients to boost their antioxidant 
concentrations and immune responses.   
 
CONCLUSION 
This study found that the majority of DR-TB patients receiving AG experienced 
some level of hearing loss during the first 6 months of the intensive phase of treatment. 
Comprehensive risk analyses and systematic literature review led to the development of a 
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prediction model of AG-induced hearing loss, and the selection of predictors was guided 
by the conceptual framework of the adverse outcome pathway on AG ototoxicity in 
MDR-TB treatment. An AG-sparing regimen is available for those at higher risk for 
developing hearing loss in South Africa, but many TB hospitals in South Africa are 
suffering from a shortage of a substitute for AG. Since there are no clear guidelines for 
healthcare providers to screen high-risk individuals for practical and cost-effective 
allocation of AG-sparing regimens, we suggest that providers consider using our 
prediction model, especially in resource-limited settings. It would help to develop 
personalized interventions by simply calculating the probability of hearing loss of each 
individual and triaging high-risk patients to AG-sparing regimens at treatment initiation 




1. Republic of South Africa Department of Health. Management of Drug-Resistant 
Tuberculosis: Policy Guidelines. Vol 161. Pretoria,Republic of South Africa: 
Department of Health; 2013. 
2. Jiang M, Karasawa T, Steyger PS. Aminoglycoside-Induced Cochleotoxicity: A 
Review. Frontiers in cellular neuroscience. 2017;11:308. 
3. Huth ME, Ricci AJ, Cheng AG. Mechanisms of aminoglycoside ototoxicity and 
targets of hair cell protection. International journal of otolaryngology. 2011:937861. 
4. WHO. WHO treatment guidelines for drug-resistant tuberculosis, 2016 updates. 
World Health Organization. Geneva, Switzerland: World Health Organization; 2016. 
5. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic 
and Cox regression. American journal of epidemiology. 2007;165(6):710-718. 
6. Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation study of 
the number of events per variable in logistic regression analysis. Journal of clinical 
epidemiology. 1996;49(12):1373-1379. 
7. Ogundimu EO, Altman DG, Collins GS. Adequate sample size for developing 
prediction models is not simply related to events per variable. Journal of clinical 
epidemiology. 2016;76:175-182. 
8. Marcotti W, van Netten SM, Kros CJ. The aminoglycoside antibiotic 
dihydrostreptomycin rapidly enters mouse outer hair cells through the mechano-
electrical transducer channels. The Journal of physiology. 2005;567(Pt 2):505-521. 
 
188 
9. Marks SM, Flood J, Seaworth B, et al. Treatment practices, outcomes, and costs of 
multidrug-resistant and extensively drug-resistant tuberculosis, United States, 2005-
2007. Emerging infectious diseases. 2014;20(5):812-821. 
10. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term 
aminoglycoside treatment in patients with tuberculosis. The international journal of 
tuberculosis and lung disease : the official journal of the International Union against 
Tuberculosis and Lung Disease. 2002;6(7):622-627. 
11. Sturdy A, Goodman A, Jose RJ, et al. Multidrug-resistant tuberculosis (MDR-TB) 
treatment in the UK: a study of injectable use and toxicity in practice. The Journal of 
antimicrobial chemotherapy. 2011;66(8):1815-1820. 
12. Isaakidis P, Varghese B, Mansoor H, et al. Adverse events among HIV/MDR-TB 
coinfected patients receiving antiretroviral and second line anti-TB treatment in 
Mumbai, India. PloS one. 2012;7(7):e40781. 
13. Sharma V, Bhagat S, Verma B, Singh R, Singh S. Audiological Evaluation of Patients 
Taking Kanamycin for Multidrug Resistant Tuberculosis. Iranian journal of 
otorhinolaryngology. 2016;28(86):203-208. 
14. Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis 
patients on aminoglycoside treatment with long term follow-up. BMC ear, nose, and 
throat disorders. 2007;7:5. 
15. Hong H, Budhathoki C, Farley JE. Increased risk of aminoglycoside-induced hearing 
loss in MDR-TB patients with HIV coinfection. The International Journal of 
Tuberculosis and Lung Disease. 2018;22(6):667-674. 
 
189 
16. Rzewnicki I, Olszewska E, Rogowska-Szadkowska D. HIV infections in 
otolaryngology. Medical Science Monitor : International Medical Journal of 
Experimental and Clinical Research. 2012;18(3):RA17-RA21. 
17. Prasad HKC, Bhojwani KM, Shenoy V, Prasad SC. HIV manifestations in 
otolaryngology. American Journal of Otolaryngology. 2006;27(3):179-185. 
18. Ivanov AV, Bartosch B, Isaguliants MG. Oxidative Stress in Infection and 
Consequent Disease. Oxidative Medicine and Cellular Longevity. 
2017;2017:3496043. 
19. Aukrust P, Luna L, Ueland T, et al. Impaired base excision repair and accumulation 
of oxidative base lesions in CD4+ T cells of HIV-infected patients. Blood. 
2005;105(12):4730-4735. 
20. Sablonnière R, Auger E, Taylor DM, Crush J, McDonald D. Social change in South 
Africa: A historical approach to relative deprivation. British Journal of Social 
Psychology. 2013;52(4):703-725. 
21. Ferreira L. FACTSHEET: Social grants in South Africa – separating myth from 
reality. In: Check A, ed2015. 
22. World Health Organization. Addressing Poverty in TB Control: Options for National 
Programmes. In: Organization WH, ed. Geneva, Switzerland: World Health 
Organization; 2005. 
23. Barter DM, Agboola SO, Murray MB, Barnighausen T. Tuberculosis and poverty: the 




24. Avent ML, Rogers BA, Cheng AC, Paterson DL. Current use of aminoglycosides: 




Date Revised: 11/27/2018 
CURRICULUM VITAE 




Johns Hopkins University School of Nursing 
525 North Wolfe Street 
Baltimore, MD 21205, USA  
E-mail: hhong13@jhu.edu 
Cell phone: 1-312-919-8349 
   
EDUCATION  
2018  Doctor of Philosophy, Johns Hopkins University, Baltimore, MD, USA 
(Expected) 
2013 Master of Science in Nursing, University of Illinois at Chicago, Chicago, 
IL, USA 
2006 Bachelor of Science in Nursing, Pusan National University, Busan, 
Republic of Korea 
 
CURRENT LICENSE AND CERTIFICATION  
2014 Certified Registered Family Nurse Practitioner, Maryland, USA; No. 
R213320 
 2014  Registered Professional Nurse, Maryland, USA; No. R213320 
 2013  Advanced Practice Registered Nurse, Illinois, USA; No. 209010839 
2013 Family Nurse Practitioner, Board-Certified, American Nurses 
Credentialing Center, USA; No. 2013015194 
 2011  Registered Professional Nurse, Illinois, USA; No. 041395424 
 2008  Registered Professional Nurse, New York, USA; No. 596371 
 2006  Registered Professional Nurse, Republic of Korea; No. 220526 
  
PROFESSIONAL EXPERIENCE 




2016–2017 Research Assistant, Johns Hopkins University School of Nursing, 
Baltimore, MD 
2015–2016 Research Assistant, Towson University, Towson, MD 
2015 Teaching Assistant, Principles of Pharmacology, Johns Hopkins 
University School of Nursing, Baltimore, MD 
2015  Research Assistant, Johns Hopkins Hospital Moore Clinic, Baltimore, MD 
2014–present Family Nurse Practitioner, MinuteClinic, LLC., Rockville, MD 
2013–2014 Family Nurse Practitioner, Korean American Community Services, 
Chicago, IL 
2011–2013 Research Assistant, University of Illinois at Chicago, Chicago, IL 
2011 Teaching Assistant, Biostatistics, University of Illinois at Chicago, 
Chicago, IL 
2010  Clinical Research Nurse, Busan Paik Hospital, Busan, Republic of Korea 
2006–2009 Registered Nurse, Kangbuk Samsung Hospital, Seoul, Republic of Korea 
 
HONORS AND AWARDS  
2018  Dr. Scholl Foundation Dissertation Scholarship 
2017–2018  F31 Ruth L. Kirschstein National Research Service Award Predoctoral 
Fellowship, NIH 
2017  Sigma Theta Tau International Global Nursing Research Grant 
2017  Sigma Theta Tau International Association of Nurses in AIDS Care Grant  
2017  Global Korean Nursing Foundation Scholarship  
2017 Dean’s Travel Award, Center for Global Initiatives, Johns Hopkins School 
of Nursing 
2017 International 3MT® Exhibition at the USETDA/NDLTD Symposium, 
Third Place 
2017   Maryland State Thesis Showcase, Second Place 
2017 Johns Hopkins University Three-Minute Thesis (3MT®) Competition 
Finalist 
2016–2017 Johns Hopkins School of Nursing Graduate Research Fellowship  
2015–2016 TL1 Predoctoral Clinical Research Training Program Trainee, NIH 
 
193 
2015 Johns Hopkins University Global Health Established Field Placement 
Award 
2015  Johns Hopkins School of Nursing Professional Development Award 
2013  Virginia M. Ohlson Scholarship 
2013  Midwest Nursing Research Society Student Poster Award, First Place 
2012  Academy of International Leadership Development Award 
2012 Induced, Sigma Theta Tau International Honor Society, Alpha Lambda 
Chapter 
2012  Korean American Scholarship Foundation Award 
2011  Academy of International Leadership Development Award 
2011–2013 Nursing Scholarship, University of Illinois at Chicago College of Nursing 




Dissertation Research  
 
2016−2018 Predicting Aminoglycoside-Induced Hearing Loss Among Multidrug-
Resistant Tuberculosis (MDR-TB)-Infected Individuals in South Africa 
 The goal of this study is to develop a prediction model of aminoglycoside-
induced hearing loss for MDR-TB patients in South Africa. This 
secondary data analysis uses a prospective cohort study design nested 
within an ongoing 5-year cluster-randomized trial in South Africa (R01 
AI104488, PI: J. Farley).   





2016−2017 Implementing HIV Evidence-Based Interventions for African American 
Women in Church Settings 
 The purpose of this church-based intervention study was to test the effect 
of the addition of a peer education network intervention—Self-Help in 
Eliminating Life-Threatening Disease (SHIELD)—as an implementation 
strategy to promote acceptability and maintenance of Sister to Sister, an 
 
194 
evidence-based HIV risk-reduction intervention for African American 
women in church settings, and to examine the role of organizational 
variables on implementation.  
PI: Jennifer M. Stewart, PhD, Johns Hopkins University School of 
Nursing 
Agency: NIH/NIMH: K23 MH106378  
Role: Research Assistant–Recruitment, enrollment, retention and follow-
up with church readers and educators, and leading church leader training 
as an interventionist, as well as in manuscript preparation. 
 
2015−2018 A Nurse Case Management Intervention to Improve MDR-TB/HIV 
Coinfection Outcomes 
The purpose of this cluster-randomized trial is to evaluate the outcome of 
nurse case management on treatment outcomes for MDR-TB/HIV 
coinfected patients in South Africa. 
PI: Jason E. Farley, PhD, Johns Hopkins University School of Nursing 
Agency: NIH/NIAID: R01AI104488   
Role: Research Resident- Conducting preliminary data QA/QC, data entry 
with cleaning/management, data analysis and manuscript preparation. 
 
2015            Stop Community MRSA Colonization Among Patients (SUSTAIN) 
This randomized controlled trial tested a household-level intervention for 
MRSA decolonization in people living with HIV  
 PI: Jason E. Farley, PhD, Johns Hopkins University School of Nursing 
 Agency: Robert Wood Johnson Foundation 
Role: Research Assistant- Recruitment, enrollment, retention/follow-up, 
biospecimen collection, and preliminary data entry 
 
2011−2013 Dispelling Cultural Myths to Promote Early Detection of Breast Cancer in 
African American Women 
This cross-sectional study collected large-scale survey data related to 
cultural beliefs contributing to disparities in breast cancer among African 
American women to understand the beliefs and perceptions about breast 
cancer screening and treatment, and the barriers to initiating treatment. 




Agency: The Institute for Health Research & Policy, University of Illinois 
at Chicago 
Role: Research Assistant- Conducting preliminary data entry, data 
cleaning and management, and data analysis 
2009−2010 Establishment of Nationwide Prospective Registration System for 
Amyotrophic Lateral Sclerosis (ALS) 
This multicenter cross-sectional study collected large-scale survey data to 
identify the current status of ALS diagnosis and management in Korea and 
to compare the results with those from other countries.  
PI: Jong Seok Bae, MD, Department of Neurology, Busan Paik Hospital, 
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